Abscess
Anti-inflammatory agent effects, In-111 IgG, 695(ab)
detection, comparison of In-111 Merc and oxine, 438
tc-99m albumin colloid leukocytes, location of infectious foci, 574(ab)
tc-99m HM-PAO, evaluation for leukocyte labeling, 638(ab)
Absorptiometry
bone densitometry asserts clinical role despite lack of reimbursement, N267
dual-photon. See Dual-photon absorptiometry single-photon. See Single-photon absorptiometry
Academic Council, SNM councils report at Winter Meeting, N802
Acetate, C-11 labeled, myocardial tricarboxylic acid cycle tracer, 61(ab)
Acquired immunodeficiency syndrome (AIDS) ARC and, Ga-67 scintigraphy in, 1103
chest scans, Ga-67, 1107
children, Ga scanning in lymphoid interstitial pneumonitis, 1915
Ga-67 lung uptake in, 1793(ab)
Ga-67 scintigraphic patterns, 648(ab)
Guidelines for radiation safety, AIDS prevention, possible conflict, N806
liver spleen scans in, 1792(ab)
nuclear medicine role in, 1790(ab)
with ICP, In-111 leukocytes and gallium imaging, 695(ab)
Adductor insertion avulsion syndrome, bone scanning in, 1835
Adenopathy, hilar and mediastinal, tumor vs. sarcoidosis using TI-201, 561(ab)
Adrenal glands
abnormal, Cushing's syndrome, I-131 NP-59 in, 640(ab)
localization of I-123 IMP in, 409(ab)
nonhyperfunctioning mass, I-131 NP-59 uptake, 640(ab)
pheochromocytoma, dosimetry of I-131 MIBG, 687(ab)
primary aldosteronism, Cushing's syndrome and, iodochlorhydroxyquinoline and CT in, 640(ab)
silent mass, functional and scintigraphic evaluation, 1401
Adrenal medulla, normal, hypertension, I-123 MIBG uptake in, 319
Adrenergic nervous system integration and function, metaiodobenzylguanidine, 1620
mapping, metaiodobenzylguanidine, 1625
Adrenoleukodystrophy, imaging, 524
Adrenomedullary cells, I-125 MIBG and norpinephrine release, acetycholine stimulated and basal, 639(ab)
Adult respiratory distress syndrome, acutely septic primates, In-111 leukocyte migration in, 649(ab)
Aging, dementia, brain, PET, 431
AIDS-related complex (ARC) AIDS and, Ga-67 scintigraphy in, 1103
Ga-67 scintigraphy, 402(le)
Algorithms convolution, uniform attenuation in SPECT and, 677(ab)
reconstruction
Gibbs model for emission computed tomography, 677(ab)
SPECT image reconstruction, 566(ab)
Alpha-aminobutyric acid, Ga-67 citrate and, rat sepsis model, 693(ab)
Alzheimer's disease C-11 pyruvate metabolism, cerebrum, 700(ab)
functioning maps, FDG rate constants, 699(ab)
Ambulatory cardiac monitoring device left ventricular dysfunction, chest pain and, CAD patients, 671(ab)
unstable angina, CAD and left ventricular dysfunction, 672(ab)
American Association of Physicists in Medicine (AAPM), AAPM explores antibody dosimetry, bone osidometry, PET, N1515
American Board of Nuclear Medicine (ABNM), ABNM adopts recertification policy, N280
American College of Nuclear Physicians (ACNP), Quality Assurance and Practice Certification Committee, N135(le)
Amides, chemistry and design implications, 593(ab)
Amino acids biodistribution, acute sepsis and abscess formation, 693(ab)
methionine and leucine, incorporation in brain tumor, 59(ab)
uptake, tumor necrosis factor, 640(ab)
Amyl nitrate, thallium imaging and, detection of CAD, 597(ab)
Asialo ganglioside, dynamic assessment, scintigraphic balloon photograpy, 660(ab)
Angiography
digital subtraction, ventilation-perfusion scan comparison, pulmonary embol, 584(ab)
left ventricular volume measurement, 401(le)
PET comparison, exercise ability and, 261(ab)
Angiography, radionuclide
to total hepatic blood flow, 551(ab)
automatic ventricular edge detection, 677(ab)
biventricular ejection fraction, flow and volume measurements, 950
first transit studies, reproducibility, 261(ab)
great vessels, congenitally corrected transposition of, 116
hepatic hemangioma, differentiation from hepatocellular carcinoma, 688(ab)
indices of left ventricular function, diagnosis of CAD and, 671(ab)
left-ventricular regional dysenergy, 1725
left ventricular volume calculation, assessment of Em, 578(ab)
MIBI renography and, renal artery flow defects, 613(ab)
reproductibility of sequential rest and exercise, 578(ab)
sequential torsion, appendix testis, 119
subclavian vein obstruction, TI-201, 254(le)
sublingual nifedipine effects, forearm venous capacitance, 717(ab)
Angioplasty
following thrombolyis, TI-201 scintigraphy, enhanced myocardial salvage, 674(ab)
percutaneous transluminal coronary, changes in myocardial perfusion reserve after, 1262
Angioscintigraphy, hepatic, portal venous hot spot, 689(ab)
Anorexia nervosa
gastric emptying studies with, 816
stress fractures and reduced bone mineral density, 1506(le)
Anti-antibody enhancement, radioummunodetection, experimental and clinical studies, 1604
Antibodies
See also specific type
FDA releases updated "points to consider" for antibody products, N1520
non-labeled, background reduction by immunoscintigraphy, 712(ab)
radiometabolic, reversal of sequence, 723(ab)
Antidepressant drugs, distribution of IMP and, 354
Antigens, density, tumors, new in vitro method, 719(ab)
Antiglobulins, responses, monoclonal antibody, 615(ab)
Anti-inflammatory agents, radiolabeled immunoglobulin scans, focal inflammation, 695(ab)
Anti-monoclonal antibodies, radioummunodetection, cancer, 652(ab)
Anti-murine antibodies, hams-murine antibody complexes and, 614(ab)
Anti-platelet antibodies
clot localization, experimental pulmonary emboli, 718(ab)
In-111 and In-125, behavior in experimental pulmonary emboli, 720(ab)
Anti-tumor antibodies, status report, 1786(ab)
Aorta, atherosclerotic lesions, experimental, rabbit, 610(ab)
Aortic root, perivascular abscess, Ga-67 and NMR, 1616
Arterial thrombus, detection with Ga-67 DD-fibrinogen, 639(ab)
Arteriography, total-body, intravenous radionuclide, 40(ab)
Arthrography, dual isotope, femoral component of prothetic hips, 565(ab)
Arthroplasty
knee
asymptomatic, radiophosphate uptake in, 1546
postoperative bleeding, Tc-99m RBC, 565(ab)
radiophosphate uptake in, 586(ab)
Artifacts

Page numbers followed by (ab) indicate abstracts.
Page numbers followed by (le) indicate letters.
N preceding a page number indicates an article appearing in "Newswire."
Bone densitometry

diagnosis by radioimmunoscintigraphy, 585(ab)
In-111 WBC vs. other methods, 586(ab)
infarction of second metatarsal, scintigraphic manifestation, 249
In-111 leukocytes and, culture proven acute osteomyelitis, 694(ab)
malignant disease, samarium-153 EDTMP and, 505
metastatic pain, treatment with Strontium-89, 553(ab)
mineral density
caucasian female volunteers, 664(ab)
comparison in both hips, 629(ab)
dual-photon absorptiometry, 629(ab)
endomietriosis, 628(ab)
ersors in longitudinal measurements, dual-photon absorptiometry, 1751
femoral, ROI size and angulation effects, 179(ab)
gamma camera measurement, 629(ab)
medullary thyroid carcinoma, 685(ab)
prolonged maintenance hemodialysis effects, 630(ab)
regional differences in lumbar spine, 663(ab)
spinal, loss with inactivity, 260(ab)
stress fracture with prior anorexia nervosa, 1506(ab)
trabecular and cortical contents, 686(ab)
xenon multiview proportional counter, 641(ab)
mineral loss, femur, spinal cord injured patients, 179(ab)
multiphase scanning, postprandial blush in, 1550
non-infected closed fractures, In-111 WBC uptake, 586(ab)
primary cancer, Sm-153-EDTMP as a radiotherapeutic agent, 709(ab)
quantitative scintigraphy, hyperparathyroidism, 455
regional measurements, osteoporotic fractures of spine and distal forearm, 960
scanning
ductor insertion avulsion syndrome, 1835
bacterial lumbar spondylitis, 254(ab)
eta sign in, 1229(ab)
extended severity uptake, ischemia and, 108
pathophysiology, 585(ab)
rheumatic disorders, 262(ab)
scan/positive findings, breast cancer, 606(ab)
scintigraphy
comparison with NMR, spinal lesions, 590(ab)
sufficiency fractures and, 605(ab)
patelar tendinitis, 1768
keletal tuberculosis, resembling metastatic disease, 1507(ab)
esternal lesions, breast cancer, 606(ab)
stress fractures, interpretation of scintigraphic findings, 452
Te-99m DTPA uptake, blood clearance and, 1461
tertiar syphilis involving, radionuclide imaging in, 1047
therapeutic agents, Sm-153, 495
thromboembolism, scintigraphy, osteochondritis dissecans, 650(ab)
trauma, Te-99m phosphate imaging, glycercolcoid effects, 606(ab)
tiple phase scan
simultaneous In-111 WBC, neuropathic foot disease, 649(ab)
tissue viability in frostbite injury, 665(ab)
upright spine, scintigraphy, 664(ab)
Bone densitometry
bone densitometry asserts clinical role despite lack of reimbursement, N267
OHTA advocates HCFA to deny Medicare coverage for SPA, DPA, N1656
Bone marrow
investigation, Te-99m microcolloid and MRI, 705(ab)
malignant lymphoma disease, 609(ab)
In-111 WBC as an imaging agent, 574(ab)
masses
examination of liver with radicociloid, 184
liver examination with radicoloid, 1640(e)
transplantation, I-131 antymyeloid monoclonal antibodies, 692(ab)

Book reviews
Bone Scanning in Clinical Practice, 1643
Cardiac Imaging: New Technologies and Clinical Applications, 929
Essentials of Nuclear Medicine Science, 1511
Immunoscintigraphy, 258
Introduction to Radiological Physics and Radiation Dosimetry, 1066
Magnetic Resonance Imaging and Spectroscopy, 1367
Magnetic Resonance Imaging of the Central Nervous System, 1232
Magnetic Resonance Imaging: Principles and Applications, 140
Magnetic Resonance of the Musculoskeletal System, 1511
NCNP Report 91: Recommendations on Limits for Exposure to Ionizing Radiation, 1929
NMR in Medicine: The Instrumentation and Clinical Applications, AAPM Monograph No. 14, 1232
Nuclear Cardiac Imaging: Principles and Applications, 1066
Nuclear Magnetic Resonance Imaging in Medicine and Biology, 1928
Nuclear Medicine in Clinical Oncology, 548
Nuclear Medicine in Urology and Nephrology, 292
Nuclear Medicine Therapy, 1233
Nuclear Pharmacy, 1784
Nuclear Techniques in Diagnostic Medicine, 1511
Numerical Recipes: The Art of Scientific Computing, 547
Patient Irradiation in Diagnostic Nuclear Medicine, 1985, 257
PET and NMR: New Perspective in Neuro Imaging and in Clinical Neurochemistry, 1784
Physics and Engineering of Medical Imaging, 1784
Physics in Medicine and Biology Encyclopedia, 139
Physics in Nuclear Medicine, 930
Progress in Radiopharmacy, 1368
Radiation Risks to the Developing Nervous System, 1233
Radioactive Waste—Proceedings of the Twenty-First Annual Meeting of the National Council on Radiation Protection and Measurements, 258
Radiouclide Imaging of the GI Tract, 1928
Radionuclide Imaging Techniques, 1367
Radiopharmacy and Radiopharmacology Yearbook, 257
SPECT Single-Photon Emission Computed Tomography: A Primer, 548
Table of Radioactive Isotopes, 140
Technetium in Chemistry and Nuclear Medicine, 1643
1986 Yearbook of Diagnostic Radiology, 139
1986 Yearbook of Nuclear Medicine, 547
Boundary determination, organ, SPECT visualization, 334
Bowel disease, inflammatory, isotopic index of disease activity, 688(ab)
Brain abnormal PET, early Alzheimer's disease, 645(ab)
acute infarction, Tc-99m HM-PAO SPECT, 622(ab)
aging and dementia, PET, 431
astrocytoma, TI-201, 706(ab)
blood flow. See Blood flow, cerebral blood flow tracers, TI-201 DDC and I-123 IMP, 481
blood perfusion, Tc-99m HM-PAO, 191
caudate D2 dopamine receptor density, PET, 700(ab)
cerebral extraction efficiency, Te-99m oxine complexes, 729(ab)
cerebrovascular disease, Tc-99m HM-PAO and RBC SPECT, 600(ab)
C-11 eticlopride synthesis, PET, 625(ab)
C-11 L-methionine accumulation, PET, 645(ab)
C-11 pyrilamine, synthesis and biodistribution, 624(ab)
comparative imaging, I-123 amphetamines and Tc-99m HM-PAO, 569(ab)
complex partial seizure focu, SPECT I-123 HIPDM imaging, 600(ab)
cortical and subcortical metabolism, anxiety effects, normals and schizophrenics, 655(ab)
cryptogenic West syndrome, Xe-133 SPECT in, 592(ab)
D3 dopamine receptors
F-18 fluorocarbazepine, 612(ab)
manic-depressive patients, 611(ab)
primates, 611(ab)
defol removal, C-11 choline, 136(ab)
delayed scan, I-123 IMP SPECT, 559(ab)
dermented patients, Xe-133 inhalation SPECT, 599(ab)
dopamine and serotonin receptors, equilibrium binding kinetics, 611(ab)
fluorodeoxyglucose metabolism, deoxyglucose tissue concentration with F-19 NMR and F-18 PET, 655(ab)
gliomas, PET evaluation of, 1123
glucose metabolism
aging, systemic health factors in, 601(ab)
F-18 deoxyglucose studies, 53, 1667
schizophrenia on and off medication, 702(ab)
glucose transport, I-123 18F PET studies, 571(ab)
high resolution SPECT imaging
astigmatic collimator, 576(ab)
cone beam collimator, 577(ab)
fan beam collimator, 576(ab)
I-123 HIPDM, with fan beam collimation, 570(ab)
Huntington's disease, glucose metabolism and DNA polymorphism studies, 655(ab)
IB2M and NMSP in, D-2 dopamine receptor binding of, 1930(ab)
I-123 HEAT, radiodensity of, 1745
I-123 HIPDM, radioactive iodine exchange reaction, 360
I-123 IMB distribution, cognitive challenge and, 592(ab)
I-125 IMP binding and subcellular distribution, 702(ab)
diagnosis of ischemia vs. infarction, 409(ab)
distribution, temporal changes in, 623(ab)
images, Metz filters for processing, 677(ab)
imaging
I-125 IPPA preparation and biodistribution, 571(ab)
SPECT I-125 IMP, aphasias vs. normals, 550(ab)
intracranial hemorrhage, CK-BB levels, premature infant, 718(ab)
lead-203 DDC, perfusion agent, mice, 723(ab)
local, quantitative visualization, 698(ab)
lumped constant, deoxyglucose model, 471
MAO-B activity, C-11 DMPEA kinetics, 1006
N-nitrosourea synthesis, tumor, 625(ab)
perfusion imaging, 1364(e)
perfusion imaging agents, SPECT, 1012
perfusion SPECT, Tc-99m HM-PAO, 569(ab)
PET
C-11 deprenyl, baboon, 624(ab)
copper radiopharmaceuticals, 407(ab)
prazosin in treatment, elderly patients, 623(ab)
prazosin-neuroreceptor interaction, four-compartment model, 681(ab)
refractory neonatal seizures, PET in surgical selection, 646(ab)
“slices of life,” scientific highlights, SNM 34th
Annual Meeting, 1987, N1235
structures on O-15-H2O PET scans, NMR and stereotactic method comparison, 702(ab)
study of two behavior states, PET/FGD procedure, 852
synthesis, radiopharmaceuticals, 635(ab)
Tc-99m HM-PAO decomposition, aqueous media, 593(ab)
kinetcs, first minutes after injection, baboon, 593(ab)
vs. TI-201 DDC, subcellular distribution, 593(ab)
Tc-99m HM-PAO SPECT
epileptic patients before and during Wada test, 1763
initial experience with, 1657
Tc-99m scintigraphy, 1787(ab)
TI-201 scintigraphy, increasing specificity, 658(ab)
tomoscopy, subacute strokes, Tc-99m HM-PAO and I-123 IMP, 623(ab)
tumors
carolinecin, 561(ab)
carolinecin (anti-Monoclonal antibody, 561(ab)
carolinecin and I-123 IMP, 623(ab)
imaging
assessments of estrogen receptors, 561(ab)
I-131 monoclonal antibody
carolinecin, 561(ab)
radioimmunotherapy, 573(ab)
internal mammary grafts, Xe-133, 632(ab)
milk, suppression of Tc-99m pertechnetate by perchlorate, 1187
P-31 spectroscopy, 599(ab)
tumors, radiolabeled bacterial immunomodulator, 658(ab)
Bromine-80m, labeled estrogen receptors, synthesis and biodistribution, 572(ab)
Bronchial asthma, remission, clearance of radioaerosols by bronchodilation, 1901
Bronchodilator deposition and clearance of radioaerosols, bronchial asthma in remission, 1901
Brucer, Marshall, Marshall Brucer still full of acerb wit 30 years after serving as SNM president, fight against societal radiation phobia, N1645
Budd-Chiari syndrome, typical and atypical scintigraphic aspects, 803
Calcitriol
diiododecaiodoiodonucleonic acid, localization in medullary thyroid carcinoma, 263(ab)
stability, commercial radioimmunoassay kit, 718(ab)
Calcium-45, Tc-99m MDP uptake and, ectopic bone, rats, 665(ab)
Calibrator, dose, varying geometry effects, 1478
Cal Rad Forum, Cal Rad Forum, workshop, low-level radioactive waste, N1382
Canada
Commentary: rationale for “SNM in Canada”, N10
Etienne LeBel recognized for leadership in Canadian nuclear medicine, N791
Cancer, hepatic indwelling, drainage patterns, hepatobiliary imaging, 1055
Captopril
radionuclide renal studies, renovascular hypertension, 1789(ab)
renography, 733(ab)
Goldblatt hypertension, 1171
renal baseline function and, 612(ab)
renovascular hypertension, 613(ab), 735(ab)
corticography, test, renovascular hypertension, 613(ab)
single-dose, renovascular hypertension, 1383
Tc-99m DTPA studies enhanced by, renovascular disease, 613(ab)
Carbohydrates, IgG residues, alteration by radiodination and radiochelation, 560(ab)
Carbon-11
brain pH measurement, PET, 698(ab)
thymidine labeled with, dosimetry estimates for PET studies, 683(ab)
Carbon-11 AIB, starvation effects, skeletal muscle, 659(ab)
Carbon-11 BMHIDE saturated and unsaturated, structure localization relations, 727(ab)
synthesis, biological evaluation and, 728(ab)
Carbon-11 carbon dioxide, preparation from C-11
Carbon-11-carboxylated t-dopa, routine synthesis, 1599
Carbon-11 choline, deanol removal, 136(le)
Carbon-11 deprenyl, PET, brain, baboon, 624(ab)
Carbon-11 diprenorphine, PET, studies of opiate receptors, 635(ab)
Carbon-11 DMPEA, kinetics, brain MAO-B activity, 1006
Carbon-11 eticlopride, synthesis, PET, 625(ab)
Carbon-11 IBZ, synthesis, D2 dopamine receptor imaging, 726(ab)
Carbon-11 leucine, cerebral protein synthesis, PET, 587(ab)
Carbon-11 methionine, primary lung cancer relations, PET, 658(ab)
Carbon-11 methyl benzazepine, synthesis, reductive carboxylation approach, 625(ab)
Carbon-11 methyl iodide, synthesis, 1037
origin of carrier in, 728(ab)
Carbon-11 methylketanserin, PET and, localization of serotonin-2 receptors, 600(ab)
Carbon-11 nitromethane, radiolabeling precursor, 636(ab)
Carbon-11 pyravate, metabolism, cerebrum, Alzheimer’s disease, PET, 700(ab)
Carbon-11 SCOP, radiosynthesis of, from C-11 formaldehyde, 635(ab)
Carbon-11 thymidine, development, PET imaging agent, 728(ab)
Carbon-14 amino acids, parathyroid gland autoradiography, 1447
Carbon dioxide, labeling blood cells, 1020
Carbonmonoxyhemoglobin (CEA) and, anti-monoconal antibodies, radioimmunodetection of cancer, 652(ab)
false-positive, anti-murine antibody with monoclonal antibodies, 615(ab)
In-111, radioimmaging of tumors, 637(ab)
kinesics of monoclonal antibodies, 693(ab)
Tc-99m monoclonal antibody, labeling of proteins, 721(ab)
uptake, colorectal cancer, 637(ab)
Cardioiod syndrome, I-131 MIBG diagnosis, 638(ab)
Cardioma, medullary, thyroid, Tc-99m DMSA, 561(ab)
Cardiac monitoring
ambulatory device, left ventricular dysfunction in CAD, 609(ab)
left ventricular, dual cadmium telluride detectors, 609
Cardiac output, first-pass radionuclide determination, gamma camera, 1330
Cardiology, hyperthermic, myocardial blood flow measurement using N-13 ammonia, 567(ab)
Cardiopulmonary blood volume, venous pumped, staged maximal exercise and, 650(ab)
Cardiovascular Council, SNM councils report at Winter Meeting, 1182
Cardiovascular disease, SPECT, I-123 iodocarbamethine, 622(ab)
Carcinoid artery, I-131 monoclonal antibody administered through, glioma, 603(ab)
Cardiac artherosclerosis, anti-thrombotic drug effects, platelet deposition, In-111 platelets and Tc-99m HSA, 701(ab)
Cations, heart, chemistry of, 1351
Cerebellum, glucose metabolism, fluorine-18 FDG and PET, 1667
Cerebral infarction, focal hyperemia in, demonstration with I-123 IMP, 1920
Cerebral ischemia
clinical outcome, metabolic and structural abnormalities and, 633(ab)
I-123 IMP, Tc-99m HM-PAO SPECT and, 623(ab)
study of regional blood flow, SPECT, 633(ab)
Cerebrovascular disease, I-123 IMP and Tc-99m
Certification

HM-PAO distribution, early and late SPECT, 59(ab)
Certification, ABNM adopts recertification policy, N280
Charged particle camera, high resolution charged, stable isotopes in cells and tissues, 697(ab)
Chelating agents
avidin system, imaging tumors, 722(ab) bifunctional
In-111 bimane potential for, 657(ab)
In-111 entrapment in liver, 657(ab)
In-111 fragment E1, 657(ab)
CE-DTS, localization of Tc-99m in tumor xenografts, 720(ab), 730(ab)
In-111 monoclonal antibodies, human neutrophils, 720(ab)
selective bifunctional, antibody modification, Ga-67(ab)723(ab)
Chemotherapy, malignant brain tumors, assessment with cisplatin PET, 1844

Chernobyl
Chernobyl, decontaminate world threatened by fallout, risk misperception, N933
Chernobyl, physicians' role examined in planning response to nuclear accidents, N413
Commentary: Chernobyl predictions and the Chinese contribution, long-term health effects, N423
lessons from, 1790(ab)
thyroid screening of travelers after, I-131, 535
China, SNM Asia tours, two international nuclear medicine conferences in China, N1806
Cholecystitis, cholecintigraphic diagnosis, morphine in, 596(ab)
Cholecystokinin, analogues, comparison by RIA and RRA, 568(ab)

Cholecintigraphy
cholecystokinin, fundal adenomyomatosis, 1771 reliability, biliary atresia, 716(ab)
rim sign in, 1679
Choriongonadotropin, immunossay for, discordant inter-kit results, 719(ab)
Chromatography, lectin affinity, detection of radiolabeled IgG carbohydrate perturbations, 265(ab)
PET, chemotherapy assessment, malignant brain tumors, 1844
Cobalt-57, dose calibrator response, varying geometry effects, 1478
Cocaine, chronic users, cerebral blood flow defects in, 655(ab)

Cloacelping time, improved, estimation theory, 695(ab)

Collimator
astigmatic, high resolution SPECT, brain, 576(ab)
cone beam
3-D SPECT images, variance distribution in, 678(ab)
high resolution SPECT, brain, 577(ab)
fan beam
high resolution I-123 HIPDM SPECT, brain, 570(ab)
high resolution SPECT, brain, 576(ab)
In-111 SPECT, development of, 696(ab)
optimal resolution, complex estimation, 680(ab)
pinhole
metastasis, fracture, and infections of the spine, 447
transverse SPECT, 678(ab)
slant and parallel hole, measurement, SPECT, 1592

Colloid shift, following trauma, 1366(e)

Colonic transit, dietary fiber effects, colonic transit scintigraphy, 660(ab)
Colonic carcinoma
monoclonal antibody localization, tumor-seeking agents, 709(ab)
monoclonal anti-colon/ovarian antibody, potential imaging agent, 710(ab)
Colonic transverse scintigraphy, colonic transit, dietary fiber effects, 660(ab)
Colorectal cancer, uptake of In-111 anti-CEA, biological factors, 637(ab)
Colorectal carcinoma
colorectal, detection with I-131 anti-CEA, 708(ab)
intra-arterial chemotherapy, Tc-99m MAA hepatic arterial perfusion pattern in, 708(ab)

Commercial Services Council, SNM petitions for new councils: NMR and Commercial Services, N801

Committee on Nuclear and Radiochemistry, Committee on Nuclear and Radiochemistry explores nuclear medicine issues, training requirements for nuclear medicine chemists, N1519

Communication systems, picture archival and, 1786(ab)

Compromised tomography
adenoleukodytrophy, 524
attenuation, scatter and PSF correction, elimination of non-stationary effect, 660(ab)
three dimensional correlations, PET and MRI, 682(ab)

Computer Council
SNM Computer Council plans buyer's guide, N154

SNM councils report at Winter Meeting, N802

Computerization, SNM Instrumentation Council promotes electronic mail, N1656

Computers
artificial intelligence comes to the clinic, 1786(ab)
deconvolution dynamic scintigraphic studies, functional images and partition blood flow, 619(ab)
endoocardial motion, myocardic thickening and, gated perfusion imaging, 618(ab)
expert systems concepts, 680(ab)
gamma variate formation, 680(ab)
gated blood-pool analysis, 618
hough-like transformation, detection of partially visible contours, 675(ab)
lung index, Ga-67, interstitial pneumonitis, 1826
lung scans, UCLA data base, 584(ab)
optimal collimator resolution, complex estimation, 680(ab)
recent advances, 1786(ab)
regional cerebral blood flow, I-123 iodoamphetamine SPECT, 619(ab)
regional counting statistics, scintigraphic image differences, 619(ab)
TI-201 SPECT imaging, feature extraction in, 618(ab)

Computers, software
algorithm reconstruction, SPECT, 566(ab)
cardiac clinoimaging database, imaging nuclear imaging data, 652(ab)
cardiac, compartmental model, antibody dosimetry, 617(ab)
cost-effective PC-based system, bedside cardiac blood-pool processing, 669(ab)
cross-correlation function, patient motion during SPECT imaging, 97 data collection methods, error-free, PACS, 652(ab)
3D display of arterial structure, myocardial perfusion distribution, 675(ab)
diastolic shape deformity, equilibrium radionuclide angiography, 557(ab)
digital autoradiography, solid-state image analyzer, 218
expert system shells, MS-DOS based microcomputers, 679(ab)
factor analysis and condensed image, interpretation of lymphocintigraphy, 716(ab)
gamma camera, bone mineral measurement, 629(ab)
gastric emptying liquid and solid, equivalence, 563(ab)
new math for an old test, 563(ab)
generalized dosimetry schema, tumor uptake of monoclonal antibodies, 600(ab)
high resolution PET, stationary-sampling, 607(ab)
image analysis system, quantitative autoradiography, 679(ab)
interactive visual optimization, SPECT, 1192 linear and nonlinear compartmental models, techniques, 653(ab)
mapping of FDG rate constants, myocardium, 682(ab)
modified Iowa heart phantom, SPECT defect detectability, 643(ab)
multivariate segmental pattern recognition, coronary artery disease, 676(ab)
noise power spectrum, SPECT, 630(ab)
nuclear cardiac imaging, IBM PC, 679(ab)
pressure-volume loop determinations, left ventricular function, 676(ab)
radiouclide gastric emptying studies, anorexia nervosa and, 816
regional wall motion, probabilistic image, 676(ab)
resolution recovery, SPECT, 566(ab)
systems approach, information collection, PACS, 652(ab)
T4/3 functional image, derivation and properties of, 676(ab)
three-dimensional spatially-variant point spread function, SPECT, 662(ab)
treatment of axial data, three-dimensional PET, 1717
ventilation studies, Xe-133, 616(ab)
ventricular wall motion simulation, finite element method, 557(ab)

Caspase-3, molecular presentation of immunoglobulins, radiolabeling effects on, 560(ab)

Cone beam detector system, SPECT, estimating parameters of, 661(ab)
Continuous ambulatory peritoneal dialysis, Tc-SC intraperitoneal scan in, 1930(ab)
Copper, PET measurement and, cerebral blood flow, 722(ab)
Coronary artery bypass surgery, myocardial function and, 1791(ab)
Coronary artery disease (CAD)
amyl nitrite inhalation, thallium imaging and, 597(ab)
automated edge detection technique, 135(le)
submaximal exercise, 671(ab)
combined perfusion-function imaging, 597(ab)
comparative assessment, exercise electrocardiography and ventriculography, 589(ab)
3D display of arterial structure, myocardial perfusion distribution, 675(ab)
detection, analysis of ventricular filling, 837 diabetes, diprydamole thallium scintigraphy, 170(ab)
diprydamole peripheral hemodynamic response, 580(ab)
T1 myocardial SPECT, 408(ab) diprydamole thallium studies, improved criteria for interpretation, 580(ab)
evaluation of extent, Tc-99m MIBI, 655(ab) exercise thallium scintigraphy, antianginal medication effects, 644(ab)
factor analysis assessment, radionuclide ventriculography, 664(ab)
first-pass radionuclide angiography, gamma camera and Tc-178, 663(ab)
following myocardial infarction, TI-201 rotational tomography, 674(ab)
indices of left ventricular function, combined diagnosis, 671(ab)
left ventricular diastolic function, age-related changes, 670(ab)
left ventricular dysfunction ambulatory cardiac monitoring device, 609(ab)
chest pain relations, 671(ab) patients with unstable angina, 672(ab)
left ventricular functional recovery, after exercise, 579(ab)
mental stress and, ventriculography, 597(ab) multivariate segmental pattern recognition, gated blood-pool studies, 676(ab)
myocardial perfusion reserve, changes after PTCA, 1262
normal TI-201 images, strongly positive exercise ECG and, prognosis, 643(ab)
prediction of death and myocardial infarction, exercise ECG and TI-201 scintigraphy, 644(ab)
thallium scan defects, small localized, 643(ab) TI-201 imaging alternatives to dynamic exercise for, 1788(ab) emission tomography, oral diprydamole, 579(ab)
lung/heart ration of, 1531 planar studies, new approach to interpretation, 588(ab)
TI-201 and Tc-99m MIBI, quantitative comparison, 654(ab)
Coronary heart disease, Tc-99m RP-30, TI-201 comparison, 620(ab)
Coronary reperfusion, imaging with Tc-99m MIBI, comparison with microspheres, 620(ab)
Corrections appendix to article on 1393, 1927 extrapolumonary radioactivity in lung permeability measurements, 1509 figures mislabeled on 1471, 1783 figures on 526, 1065 metoclopramide misspelled, 1640 table of contents, April issue, 928, 1065 Cortical perfusion Index, evaluation of cold storage and immunosuppresion, renal 170(ab) thallium, 731(ab)
Council of Medical Specialty Societies (CMSS), organized medicine in a destabilized era, N1247
Counting statistics, regional, scintigraphic image differences and, 619(ab)
C-reactive proteins, In-111 granulocyte scintigraphy, 155 Creatine phosphokinase-MB, screening test, myocardial infarction, 568(ab)
Creutzfeld-Jakob disease, I-123 HIPDM brain imaging, 1484 Croh's disease, ileal dysfunction in, 75-SeHCAT test for diagnosis, 688(ab)
Cystography, nuclear, 204(ab)
D Deconvolution analysis application to dynamic Tc-99m DTPA, 734(ab), 735(ab) hepatobiliary SPECT, 689(ab)
Delta sign, bone scan, 1229(le) Dementia abnormal PET, early Alzheimer's disease, 645(ab)
aging and, brain, PET, 431 AIDS complex, FDG/PET correlates of neuropsychological test scores, 600(ab) SPECT, Xe-133 inhalation, 599(ab) vasoreactivity in, 407(ab)
Densityometry, bone, trabecular and cortical contents, 686(ab)
2-Deoxy-D-glucose, PET studies, cerebral malignancy, 1251 Department of Energy (DOE) Los Alamos, conflict between radioisotopes and neutrinos resolved, N1378 physics experiment may cloud future of Los Alamos nuclear medicine program, proposals for dedicated radionuclide production facility, N1371 SNM testifies in Congress on DOE research funding, DOE offers grants for epidemiologic studies, N1249 Detectors continuous two-dimensional position-sensitive, high count rate performance of, 607(ab) semiconductor, left ventricular monitoring, 609(ab)
Dextran T70, MRI tumor-enhancing agent, melanomas in nude mice, 704(ab) Diabetes, insulin immunized patients, abnormalities of I-123 insulin biodistribution, 583(ab) Diagnosis-related groups (DRGs). See Prospective Payment System (PPS) Diagnostic centers, free-standing, 1789(ab) Diethylpyrocarbonate, labeling blood cells, 1020 Digital image filtering SPECT interactive visual optimization, 1192 Metz restoration filter, 565(ab)
Digoxin, assay, renal failure, newborns, and infants, 261(ab) Diprydamole exercise and, TI-201 uptake, myocardial ischemia, 580(ab)
infusion changes with and without exercise, 579(ab) peripheral hemodynamic response, 580(ab) TI-201 and, improved criteria for interpretation, 580(ab) intravenous administration elderly patients, 670(ab) thallium in conjunction with, children, 262(ab)
oral, TI-201 emission tomography and, CAD, 579(ab) thallium scintigraphy, CAD in diabetics, 1780(le) TI-201 SPECT directional disease diagnosis, 642(ab) silent myocardial ischemia in, 580(ab)
Diuresis, volume expansion renal scan, urinary tract obstruction, 824 Dobutamine enoximone comparison, ventricular volume, 669(ab) Dopamine D1 antagonist, C-11 labeled, reductive carbosylation approach, 625(ab) Dopamine receptors D1 imaging, IBZM and NMSP in rat brain, 1930(ab) pituitary tumors, 626(ab) dynamic PET studies, F-18, 587(ab) equilibrium binding kinetics, brain, 611(ab) measurement, manic-depressive patients, 611(ab)
Dosimetry antibody, compartmental model of kinetics, 617(ab) blood radiation, acute toxicity of therapeutic I-131 MIBG, 618(ab) brake radiation dose, anthropomorphic phantom, 684(ab) generalized schema, tumor uptake of monoclonal antibodies, 680(ab) I-131 MIBG, pheochromocytoma, 687(ab) linear and nonlinear compartmental models, computer simulations, 653(ab) photons/RAD ratios, tracer labels, 683(ab) quantitative autoradiography, micro-TLD measurements and, 617(ab) radiation brain distribution and, I-125 HEAT, 582(ab) calculations of samarium-153 EDTMP, 505 ethiodol, treatment of teratoma, 582(ab) fetal, maternally administered I-131, 581(ab) I-123 excretion, breast milk, 544(le) I-123 HEAT, 1745, 1793(ab)
I-131, hyperthyroid patients, 581(ab) I-131 thyroid screening, after Chernobyl accident, 535 lymphocyte radiolabeling, 1228(le) thyroid cancer, hematologic long-term hazards, 581(ab) SR-89, between patient variation in strontium, 683(ab) Tc-99m RBC, critical organ, 684(ab) DTPA complex, attachment of, protective complex to prevent loss of In-111 fragment E1 activity, 657(ab)
Dual-photon absorptionmetry (DPA) See also Absorptiometry bone densitometry, trabecular and cortical contents, 680(ab)
bone densitometry asserts clinical role despite lack of reimbursement, N267 bone mineral density caustic white volunteers, 664(ab) comparison in both hips, 629(ab) errors in longitudinal measurements, 1751 femoral, ROI size and angulation effects, 1793(ab) healthy white and black females, 629(ab) prolonged maintenance hemodialysis, 630(ab) proximal femur, 629(ab) regional differences in lumbar spine, 663(ab) OHTA advises HCFA to deny Medicare coverage for SPA, DPA, N1656 quality control techniques and artifacts, 550(ab) spine, scintillation camera, 665(ab) Duodenogastric reflux, Ru-97 DSIDA and Tc-99m sulfur colloid evaluation, 596(ab)
Gadolinium

phosphonate complexes
myocardial MRI and, 260(ab)
NMR of myocardium, 406(ab)

Gadolinium-153
bone densitometry asserts clinical role despite
lack of reimbursement, N267

Gallium-DTPA
enhancement in early detection, acute
myocardial infarction, 704(ab)

Mn-54 DTPA comparison, biodistribution, 349
perfusion agent, myocardial, 871
polymeric T70, MRI agent for melanomas in
nude mice, 704(ab)

Gallium-153 EDTMP, localization, damaged
rat myocardium, 722(ab), 729(ab)

Galliumbladder
cholescintigraphy results, via morphine
administration, 595(ab)
differential contractility, fundal
adenomyomatosis, cholecystokinin
cholescintigraphy, 1771
motility, spinal cord injury, 596(ab)
rim sign, cholecintigraphy, 1679

Gallium
follow-up, hepatocellular carcinoma, 1792(ab)
lymphoid interstitial pneumonitis, children with
AIDS, 1915

Gallium-67
AIDS and ARC, 1103
AIDS-related lymphoma, 694(ab)
abdominal modification and radiolabeling,
bifunctional chelating agent in, 723(ab)
heart scans, patients with AIDS, 1107
citrine imaging, painful prosthesis, 926(le)
emission tomography, asbestosis, 718(ab)
high-resolution MRI, SPECT bone scintigraphy
comparison, temporomandibular joint,
1268
In-111 chloride and WBC comparison, canine

osteomyelitis model, 575(ab)
inhibition of uptake, anti-human transferrin
receptor monoclonal antibody, melanoma, 1303
lesion detectability, thresholds, 706(ab)
lung uptake, AIDS patients, 1793(ab)
MRI and, aortic root abscess, 1616
radiophosphate visualization, total knee
prosthesis, 915
relapsing Hodgkin’s disease, non-Hodgkin
lymphoma and, 1611
sarcoidosis, childhood, 716(ab)
scintigraphy
AIDS, 648(ab)
correlation with CT scanning, AIDS-related
lymphoma, 638(ab)
thymic localization of, lymphoid and
nonlymphoid tumors, pediatric patients,
293
T1-201 uptake ratio, pulmonary neoplasms,
707(ab)
total body, AIDS related complex, 402(le)
uptake
chest, previous thoracic surgery effects, 1831
inhibition by anti-human transferrin receptor
monoclonal antibody, melanoma, 603(ab)
vs. In-111 DTPA, detection of metastatic
melanoma, 573(ab)

Gallium-67 citrate
alpha-aminoisobutyric acid and, rat sepsis
model, 693(ab)
comparison with Tc-99m glucoheptonate,
pulmonary malignancies, 442
F-18 FDG comparison, lymphoma detection,
288
I-131 monoclonal antibody comparison,
lymphoma detection, 713(ab)
lung index computerization, interstitial
pneumonitis, 1826
primary pericardial mesothelioma detected by,
1210
scintigraphy, renal disease and, 732(ab)
vs. In-111 poryphyrin, detection of human
melanoma in athymic mice, 708(ab)

Gallium-67 DD-fibrogen
arterial thrombus detection, 639(ab)

Gallium-67-DFO-DAS-fibrogen
prevention of thrombus, following myocardial infarction,
left ventricle, 609(ab)

Gallium-67 FIB, thrombus, left atrium, 691(ab)

Gallium-67 monoclonal antibodies
coupling agents, tumor targeting and, 712(ab)
versus In-111 monoclonal antibodies, human
melanoma detection, 1441

Gallium-67 TTPS4, chemistry and distribution,
rabbits, 649(ab)

Gallium-68 transferrin, PET, measurement of
pulmonary vascular permeability, 1704

Gamma cameras
acceptance testing, quality control and, 1221
bone mineral assessment
physical parameters of, 629(ab)
planar and tomographic, 641(ab)
first-pass radionuclide determination, cardiac
output, 1330
gastric emptying, liquid and solid, 563(ab)
nodular thyroid disease, MR/RN correlation,
658(ab)
SPECT systems based on, noise characteristics,
696(ab)
Ta-178 and, first-pass radionuclide angiography,
663(ab)
xenon multiwire, improved scatter rejection,
698(ab)

Gamma variate function, simplified formulation,
680(ab)
Ganglioside Ga4, monoclonal antibody, targeting to
neuroblastoma, 1577

Gastric emptying
anorexia nervosa and, 816
diabetic autonomic neuropathy and, 605(ab)
Garrer-Edwards Gastric Bubble effects,
604(ab)
gender-related differences, 1204
lag phase, confirmation, 563(ab)
liquid and solid, agreement, 563(ab)
liquid and solid, Tc-99m measurement,
563(ab)
menstruating and postmenopausal women,
604(ab)
morbid obesity, 690(ab)
new math for an old test, 563(ab)
proximal and distal stomach, normal
volunteers, 605(ab)
reproducibility, 562(ab)
reproducibility of parameters, 690(ab)
Ru-97 DISIDA and Tc-99m sulfur colloid
evaluation, 596(ab)
sex and menopausal status studies, 1926(le)
systemic sclerosis, metaclopramide effects,
688(ab)
transit of fats, 563(ab)
gastroesophageal reflux, retrospective study in
children, 715(ab)
inflammatory bowel disease, In-111 leukocyte
estimation of, 659(ab)

Gastroesophageal reflux
children, 715(ab)

Gastroesophageal reflux
retroactive study, children, 715(ab)

Gastrointestinal bleeding, bleeding rates necessary
for detection, Tc-99m red blood cells, 514

Gated blood-pool studies
diastolic shape deformity, equilibrium
radiouclide angiography, 557(ab)
dobutamine infusion, pediatric patients, 621(ab)
integrated ECG analysis, list mode processing
system and, 618(ab)
ischemia, exercise electrocardiography and
ventriculography, 589(ab)
multivariate segmental pattern recognition,
coronary artery disease, 676(ab)
nuclear angiograms, sequential rest and exercise,
reproducibility of, 578(ab)
nuclear cardiac imaging, IBM PC, 679(ab)
pericardial effusions, 1419
regional ventricular contraction, 558(ab)
rotational artifact, 1536
SPECT, adult congenital heart disease, 608(ab)
T4/S functional image, derivation and properties
of, 676(ab)
thrombolytic therapy, nuclear cardiology
techniques, 632(ab)
time domain analysis, regional diastolic
function
ventricular function, valvar regurgitation and,
aortic or mitral valve lesions, 621(ab)

Gated heart studies
age effects, maximal upright exercise, 578(ab)
blood-pool scanning, SPECT, 668(ab)
determination of attenuation coefficient,
1363(le)
intracoronary thrombolysis, 135(le)
left ventricular ejection fraction, automated
computer derived, 662(ab)
left ventricular pseudoaneurysm, 918
left ventricular volume studies, 401(le)
Generators

osmium-191/iridium-191m radionuclide, oxalato osmate parent complex, 1571 tungsten-188/renium-188, radiotherapeutics, 656(ab), 657(ab)

Georg de Hevesy Nuclear Medicine Pioneer Award Citation—1986, Rosalyn S. Yalow and Solomon A. Berson, 1637

Germanium detector, scatter correction and, SPECT, 1853

Glucose

I-131 monoclonal antibody, administered through carotid artery, 603(ab)
subcutaneous and intracranial, I-131 monoclonal antibodies, 710

Glomerular filtration rate (GFR) determination, calculated of injected dose in, 264(ab)
estimation
I-123, I-125, and I-131 diatrizoate, 366
Tc-99m DTPA, 372
intravascular pressure effects, 716(ab)
measurement, Tc-99m DTPA renography, 399(le)
radiouclide determination, children, 262(ab)
three-hour volume of distribution method, 510

Glicoficocidos, Tc-99m phosphonate and, bone imaging for trauma, 606(ab)

Glucopenicoma, Tc-99m phosphonate and, bone imaging for trauma, 606(ab)

Glucose

C-14, radiometric assay of bacterial growth, 209 cerebral metabolism
aging, systemic health factors in, 601(ab)
schizophrenia, 702(ab)
transport, cerebral, I-123 IBG SPECT studies, 571(ab)
L-glutamine, metabolic fate of, transplantable tumors, 594(ab)

Glioblastomes, infiltration, drug effects on, 667(ab)

Gravity, pulmonary circulation and, SPECT, 1758

Great vessels, congenitally corrected transposition of, radiouclide angiography, 116
Grover-McKay, Maleah, Maleah Grover-McKay receives Tetralman Memorial Award, N1100

Growth plate, surgical closure of, scintigraphy, 716(ab)

H

Head, trauma, cerebellar hypometabolism, 699(ab)

Heart

allografts, rejection, anti-IL2 receptor monoclonal antibody to, 610(ab)
attribution correction, high-resolution PET, 696(ab)

Hepatic biliary imaging
biliary atresia, cholescintigraphy in, 716(ab)
carcinoma, Ga in, 1792(ab)
cholecytitis, morphine in diagnosis, 596(ab)
detection of bile leaks, 532(ab)
differential gallbladder contractility, fundal adenomyothesis, 1771
drainage patterns, indwelling hepatic cancer, 1055
false-positive, neonatal jaundice, 966
gallbladder motility, spinal cord injury, 596(ab)
GI dual radionuclide method, operative reconstruction of biliary tract, 660(ab)
hepatic functional reserve, Tc-99m NGA in estimation of, 627(ab)
In-111, bowel via the intestinal wall, 1787(ab)
I-125 PHT, hepatoma and, 628(ab)
kinetic function analyses, MRL, 703(ab)
neonatal cholestasis, enterointest string in, 660(ab)
new radiopharmaceuticals, 1790(ab)
radiouclides, radiation dose from, 1794(ab)
results of cholescintigraphy, via morphine administration, 593(ab)
scleroderma, gastroesophageal reflux, 387
sequential scintigraphy, apparent transient biliary obstruction, 1775
Tc-99m PMT, hepatocellular carcinoma, 689(ab)

Hepatocellular carcinomas

delayed imaging, Tc-99m PMT, 689(ab)
F-18 DGAL PET, 706(ab)
gallium follow-up, 1792(ab)

Hepatocyte, localization, native and DTPA conjugated monoclonal antibodies, 552(ab)

Hepatoma, treatment, I-131 lipiodol, 707(ab)

HIDA studies, liver transplants, tracer-kinetic modeling, 653(ab)

High density avalanche chamber (HDAC), positron camera, 1554

Hodgkin’s disease
gallium scanning in, 1611
with hypercalcemia, TI-201 scintigraphy, 112

Horton, Barbara K., SNM Technologist Section names Barbara Horton as distinguished honoree, National Council holds strategic planning session, N1652

Huntington’s disease
Tc-99m brain scintigraphy using SPECT, 406(ab)

Hydrocephrosis, hemodynamic changes in, Tc-99m DMSA and MRI, 598(ab)

Hypercalcemia, Hodgkin’s disease with, TI-201 scintigraphy, 112

Hypercholesterolemia, low-density lipoprotein catalysis, I-123 DLID, 717(ab)

Hyperemia, demonstration in acute cerebral infarction, I-123 IMP, 1920

Hyperparathyroidism, quantitative bone scintigraphy, 458

Hypertension
captopril renography and, 612(ab), 613(ab), 733(ab)
sцинтография тест, 613(ab)
Tc-99m DTPA studies enhanced by, 613(ab)
complication of extracorporeal shock wave lithotripsy, 1791(ab)
Goldblatt, ANF effects on Tc-99m DTPA

1952 The Journal of Nuclear Medicine
renography, 734(ab)
Goldblatt two kidney and one kidney, captopril renography in, 1171
normal adrenal medulla, I-123 MIBG uptake in, 319
renal, exchangeable sodium and body fluid spaces, 733(ab)
renovascular
captopril and radionuclide renal studies, 1789(ab)
captopril renography in, 735(ab)
renal scintigraphy in evaluation of, 1501
revascularization therapy in, 406(ab)
single-dose captopril in diagnosis, 1383
TI-201 distribution alterations, SPECT, 673(ab)

Hyperthyroidism
feline, treatment with sodium iodide I-131, 263(ab)
radiation dosimetry for I-131 administration, 581(ab)

Hypocalcemia, postoperative, parathyroid localization scans and, 583(ab)

Hypometabolism, cerebellar, after head trauma, 699(ab)

Hypothyroidism, congenital, thyroid scintigraphy in, 687(ab)

Hypoxia
imaging, misonidazole for, 68
TI-201 kinetics and, myocardial cells, 1453

I
Image processing, digital, autoradiography, 218
Image reconstruction, axial data, three-dimensional PET, 1717
Image subtraction, parathyroid scintigraphy, 582(ab)
Image transmission, digital, 681(ab)

Immunosass
51Cr-RBC method, evaluation of monoclonal antibody procedure, 718(ab)
radioassay and nonspecific, 1788(ab)

Immunoglobulins, IgG, polyclonal, detection of focal inflammation, 614(ab)

Immunolymphoectiography, In-111-labeled Tl01 monoclonal antibodies, lymphoma after, 42

Immunomodulator, radiolabeled bacterial, tumor imaging, 658(ab)

Immunoradiography, I-131 monoclonal antibody, renal cell carcinoma xenografts, 651(ab)

Immunoelectrography
background reduction by, non-labeled antibodies, 712(ab)
clinical assessment, tumor-seeking agents, 637(ab)
colon cancer, I-131 2832 imaging, 636(ab)
monoclonal antibodies, targeting radiopharmaceuticals, 561(ab)
pre-targeted, chimeric antibodies, 561(ab)
recurrences of gynecologic carcinomas, 1807

Immunotherapy, radioimmunotherapy comparison, animal model, 69(ab)

Incubation media, chelates, with In-111, platelet labeling and, 223

Indium-111
bowel activity, via the intestinal wall, 1787(ab)
differences in metabolism, 693(ab)
detection, thresholds, 706(ab)
leukocyte uptake, 256(ab)
mouse antimalanoma monoclonal antibody ZME-018, optimal tumor localization of, 25
platelet kinetics, mathematical model, 402(1e)
radiolabeled lymphocyte, 229
subcutaneously administered, lymphatic kinetics, 715(ab)
toxicity lymphocytes, 1365(le)
radiolabeled lymphocyte, 229

Indium-111 antibodies
comparison of tumor size, melanoma, 711(ab)
imaging applications, 560(ab)
long term fate, BALB-C mice, 692(ab)
non-specific Fe receptor binding, tumor detection with, 572(ab)

Indium-111 anti-CEA localizati0n, lung cancer, 615(ab)
monoclonal antibody imaging, 560(ab)
abdominal colorectal cancer, SPECT, 604
colorectal carcinoma, 710(ab)
radiolymphoscintigraphy of tumors with, 637(ab)
uptake, colorectal cancer, 637(ab)

Indium-111 antimonyas comparison with In-111 antimonyas imaging, acute myocardial infarction, 590(ab)
DTPA and, 668(ab)
heart transplant rejection, cyclosporin-treated, 663(ab)
new cardiac imaging agent, 1790(ab)

Indium-111 antimonyas f myocardial damage, 76
myocardial infarct imaging, 1671

Indium-111 bincone potential as bifunctional chelating agent, 657(ab)

Indium-111 cations, ionophoric transport, lipid bilayer membrane, 91

Indium-111 chelates, platelet labeling and, 223

Indium-111 chloride
Ga-67 and In-111 WBC comparison, canine osteomyelitis model, 575(ab)
injected prostheses, 255(1e)
In-111 WBC comparison, adult osteomyelitis, 1540

Indium-111 DTPA antibody tumor targeting, chemical modification with ester bond, 572(ab)
conjugates with different linkages, comparison, 572(ab)
entrapment in liver, proteins labeled using bifunctional chelates, 657(ab)
GI dual radiolucide method, operative reconstruction of biliary tract, 660(ab)
non-targeted, radiolabeled antibody, clot localization, experimental pulmonary emboli, 718(ab)
vs. Ga-67, detection of metastatic melanoma, 573(ab)

Indium-111 fab, renal uptake, reduction of, 716(ab)

Indium-111 f(ab')2, distribution, normal mice, 692(ab)

Indium-111 fragment E1, loss of functional activity, protective complex during attachment of DTPA groups, 657(ab)

Indium-111 granulocytes
diagnostic significance, febrile patients, 155
localization mechanism, dog model, 691(ab)
methyl-prednisolone, ibuprofen and vitamin E effects, perfused beating heart, 667(ab)
splenic activity, inflammatory bowel disease, 688(ab)

Indium-111 haptens
monoclonal antibody, radioimmunoassay detection of colon tumor model, 711(ab)
radioimmunoassay detection, normal mice, 692(ab)

Indium-111 IgG, anti-inflammatory agent effects, focal inflammation, 695(ab)

Indium-111 leukocytes accumulation, after reperfusion of ischemic myocardium, 610(ab)

Inflammation, fever, 263(ab)

Bone scans and, culture proven acute osteomyelitis, 694(ab)
cold bone defects, 820
compromising efficacy, osteomyelitis, 1931(ab)
diagnosis and staging, idiopathic pulmonary fibrosis, 616(ab)
fever of unknown origin, oncology patients, 648(ab)
gallium imaging and, AIDS with PCP, 695(ab)
infarcted bowel disease, extent and activity estimation, 659(ab)
migration, acute septic primaries, adult respiratory distress syndrome, 649(ab)
osteomyelitis, axial skeleton, 694(ab)
simultaneous 3-phase bone scan, neuropttic foot disease, 649(ab)

Indium-111 labels, labeling blood cells, 1020

Indium-111 MDP, comparison with oxine, absence detection, 438

Indium-111 monoclonal antibodies
antiinfiltrin, deep venous thrombosis detection, 1930(ab)
athymic mice, bearing human colon carcinoma xenografts, 861
biodistribution, 722(ab), 1924(le)
chelating agents for labeling, human neutrophils, 720(ab)
chronic lymphocytic leukemia with, 602(ab)
differential localization, melanoma, 709(ab)
I-131 comparison, cutaneous T-cell lymphoma imaging, 281
intratumoral injection, nude mouse-human tumor model, 712(ab)
localization, melanoma, 651(ab)
lymphoma after, immunolymphoscintigraphy, 42
melanoma detection, 1063(ab)
osteogenic sarcoma xenografts, 342
SPECT, new colliiminator for, 696(ab)
versus Ga-67 monoclonal antibodies, human melanoma detection, 1441

Indium-111 oxalate
comparison with Merc, absence detection, 438
leukocyte labeling, 1789(ab)
platelet imaging, right atrial thrombus associated with constrictive pericarditis, 1344

Indium-111 oxalate osteopontin, Tc-99m HM-PAO labeled leukocytes, inflammatory imaging, 648(ab)

Indium-111 platelets
detection of intracardiac thrombosis, blood-pool subtraction, 639(ab)
diagnostic imaging, 1789(ab)
scintigraphy, deep vein thrombophlebitis, 649(ab)
To-99m HSA, antithrombotic drug effects on platelet deposition, carotid atherosclerosis, 701(ab)

Indium-111 porphyria
synthetic, tumor imaging agents, 724(ab)
vs. Ga-67 citrate, detection of human melanoma in athymic mice, 708(ab)

Indium-111 troponin, low density lipoprotein receptors, uptake in lipoprotein tissue, 610(ab)

Indium-111 white blood cells
bone marrow imaging agent, 574(ab)
comparative efficacy of Tc-99m MDP, osteomyelitis, 586(ab)
comparison with Tc-99m HM-PAO, imaging inflammation, 574(ab)
false positive, imaging in malignancy, 562(ab)
In-111 chloride and Ga-67 comparison, canine osteomyelitis model, 575(ab)
In-111 chloride comparison, adult osteomyelitis, 1540
orthopedic prosthesis infection, comparison with other methods, 586(ab)
suspected orthopedic prosthesis infection, 551(ab)
take-up, non-infected closed fractures, 586(ab)
Indium-111 ZCE-025, pharmacokinetics and tissue distribution, 179(ab)
Infection imaging, Ga-67 and In-111, 1788(ab)
Inflammatory bowel disease, In-111 SPECT, computed tomographic correlation, 659(ab)
In memoriam
Jack W. Smith, RT (X) (N) AART, 137
Norman H. Horwitz, Ph.D., 137
Samuel R. Lerner, Ph.D., 1510
Institute of Medicine (IOM)
IOM Council on Health Care Technology, N154
Michel Ter-Pogossian elected to IOM, N1520
Instrumentation
equipment purchasing decisions, based on clinical needs and facility design, transition from planar to SPECT, PET, N278
used nuclear medicine equipment needed in developing countries, N944
Instrumentation Council
SNM councils report at Winter Meeting, N802
SNM Instrumentation Council promotes electronic mail, N1656
Insulin, I-123 labeled, abnormalities, insulin immunized diabetics, 583(ab)
Iodination, high efficiency, monoclonal antibodies for radiotherapy, 1034
Iodine-123
3-methyl-branching, myocardial lipid metabolism, 720(ab), 724(ab)
myocardial blood flow agents, 725(ab)
Iodine-123 amphetamine, brain imaging, comparative, Tc-99m HM-PAO and, 569(ab)
Iodine-123 anti-granulocyte antibodies, infectious lesions, radioimmunodetection of, 614(ab)
Iodine-123 diastrophos, glomerular filtration rate, children, 366
Iodine-123 HA, fatty acid metabolism, myocardium, 924-925(ab)
Iodine-123 HEAT biodistribution and radiation dosimetry, 179(ab)
radiation dosimetry of, 1745
Iodine-123 heptadecanoic acid, free fatty acid scintigraphy, heart, 567(ab)
Iodine-123 HIPDM brain imaging, subacute spongiform encephalopathy, 1484
comparative partial seizure foci, brain, 600(ab)
reactive iodine exchange reaction, 360
response of visual cortex, 551(ab)
Iodine-123 hippuran, comparison with Tc-99m MAG-3, renal work, 647(ab)
Iodine-123 IBG, glucose transport, cerebral, 571(ab)
Iodine-123 MB distribution, brain undergoing cognitive challenge, 592(ab)
early and late SPECT, distribution in cerebrovascular disease, 591(ab)
Iodine-123 IMP acute cerebral infarction, focal hyperemia in, 1920
adrenal gland, 409(ab)
autoradiographic comparison, cerebral blood flow tracers, 481
brain imaging cerebral blood flow tracer, 570(ab)
Metz filters for processing, 671(ab)
brain scintigraphy, diagnosis of ischemia vs. infarction, 40(ab)
cerebral blood flow, noninvasive quantitative assessment, 558(ab)
distribution, temporal changes, brain, 623(ab)
malignant melanoma, 562(ab)
Rb-82 tissue kinetics, measurement of regional myocardial blood flow, 558(ab)
SPECT chronic aphasics vs. normals, 559(ab)
delayed scan in brain, 559(ab)
Te-99m HM-PAO SPECT and, subacute strokes, 623(ab)
tracer kinetics, measurement of cerebral blood flow, SPECT, 569(ab)
Iodine-123 insulin, abnormalities, insulin immunized diabetics, 583(ab)
Iodine-123 iodoamphetamine portal hypertension, evaluation of portosystemic shunts in, 628(ab)
SPECT cardiovascular disease, 622(ab)
regional cerebral blood flow, 619(ab)
Iodine-123 iodoheptadecanoic acid, gastrointestinal transit, fats, 563(ab)
Iodine-123 IPPA myocardial extraction, cardiomyopathy, 670(ab)
TI-201 comparison, coronary artery disease, 669(ab)
Iodine-123 LDL, comparison for imaging sites, low-density lipoprotein catabolism, 717(ab)
Iodine-123 MBIG adrenergic nervous system mapping, 1625
carcinoid tumor imaging, 1907
imaging, idiopathic congestive cardiomyopathy, 667(ab)
regional washout, myocardial, sympathetic innervation and, 608(ab)
SPECT, after transmural myocardial infarction, dog model, 669(ab)
uptake hypertension and, normal adrenal medulla, 319
pheochromocytoma, parangangiomas, and neuroblastomas, 973
Iodine-123 mosolodo-t-tyroline, artificial amino acid, membrane transport measurement, 724(ab)
Iodine-123 sodium iodide, breast milk excretion, radiation dosimetry, 544(le)
Iodine-123 speiperone, high-yield labeling, SPECT, animal studies, 570(ab)
Iodine-125, chimeric monoclonal antibody, tumor specific genetically engineered, 560(ab)
Iodine-125 antibody, localization, human colon carcinoma, 709(ab)
Iodine-125 AZIDO-IPAPP, serotonin receptor agonist, irreversible, CNS, 725(ab)
Iodine-125 diastrophos, glomerular filtration rate, children, 366
Iodine-125 dimethyl fatty acid myocardial uptake and clearance kinetics DMIPP analogues, 571(ab)
measurement of myocardial fatty acid uptake, 724(ab)
Iodine-125 fibrinogen, lung transplants, hepatic effects, 654(ab)
Iodine-125 HEAT, brain distribution, radiation dosimetry and, 582(ab)
Iodine-125 IBZ, synthesis, D2 dopamine receptor imaging, 726(ab)
Iodine-125 IIDA, kinetic evaluation, isolated rat heart, 667(ab)
Iodine-125 IMP, binding and subcellular distribution, brain, 702(ab)
Iodine-125 lodo-lutetreastadecanoic acid, heart, iodoalkene and tellurium isomer, 571(ab)
Iodine-125 IPM, design and synthesis, antibody labeling kit, 726(ab)
Iodine-125 IPPA, preparation and biodistribution, brain imaging, 571(ab)
Iodine-125 MIBG adrenergic nervous system integrity, 1620
norepinephrine and, adrenomedullary cells, 639(ab)
Iodine-125 PHT, hepatobiliary imaging, hepatoma and, 628(ab)
Iodine-125 PX11195, high specific activity, novel synthesis of, 724(ab)
Iodine-131 accumulation, pericardial effusion, 133(le)
In-111 comparison, cutaneous T-cell lymphoma imaging, 281
low vs. high dose, thyroid remnant ablation, 685(ab)
maternally administered, fetal radiation dosimetry, 581(ab)
neuroendocrine tumors, 979
radiation dosimetry for, hyperthyroid patients, 581(ab)
radioactive therapy, parotid oncocyotma, 625(ab)
sodium iodide, treatment of feline hyperthyroidism, 263(ab)
therapeutic dose, undiagnosed metastases in thyroid cancer, 1881
therapy, monitoring radioactivity after, 1064(ab)
thyroglobulin assays and, correlation with TI-201, follow-up with thyroid cancer, 685(ab)
thyroid screening, Chernobyl accident, 535
total body scan, differentiated thyroid carcinoma, 683(ab)
whole-body thyroid scans, hepatic visualization, 1408
Iodine-131 Anti-CEA anti-antibody enhancement, experimental and clinical studies, 1604
polyclonal, detection of metastatic colorectal and other carcinoma, 708(ab)
Iodine-131 anti-IA, autologous bone marrow transplant and, B-cell lymphoma, 692(ab)
Iodine-131 diastrophos, glomerular filtration rate, children, 366
Iodine-131 HIPDM lung uptake model, 203
single-pass multiple indicator dilution technique, rabbit model, 487
Iodine-131 hippuran captopril renography, 733(ab)
split renal function, renovascular hypertension or urinary obstruction, 731(ab)
Iodine-131 iodomethyluriccholesterol, localization of ovarian dysfunction, 685(ab)
Iodine-131 lipiodol, hepatoma treatment, 707(ab)
Iodine-131 MIBG carcinoid syndrome, 658(ab)
correlations with CT and MRI, detection of pheochromocytoma, 639(ab)
failure, small cell lung carcinoma, 1230(le)
familial malignant nonfunctional
paraganglioma, 528
medullary carcinoma, thyroid, 576(ab), 1820
metastatic pheochromocytoma and
neuroblastoma, extremities, 315
mouse neuroblastoma, 225(le)
nuclear crest tumors, 1787(ab)
diagnosis and therapy, 308
pheochromocytoma and neuroblastoma
treatment, 627(ab)
safety of therapy, advanced neuroblastoma,
628(ab)
therapeutic, acute toxicity of, blood radiation
dosimetry, 618(ab)
uptake, medullary thyroid carcinoma, 265(ab)
uptake and dosimetry of, pheochromocytoma,
687(ab)
Iodine-131 monoclonal antibodies
against synthetic carbohydrate antigens, cancer
immunoscintigraphy, 712(ab)
biodistribution, 722(ab)
clinical assessment, immunoscintigraphy,
637(ab)
cutaneous T-cell lymphoma, retreatment,
603(ab)
distribution, carotid artery administration,
glioma and, 603(ab)
Ga-67 citrate comparison, lymphoma detection,
713(ab)
gliomas, subcutaneous and intracranial, 710(ab)
high activity, pharmacokinetics of, 533(ab)
immunoradiotherapy, renal cell carcinoma
 xenografts, 651(ab)
immunoreactive fraction, altering labeling
 parameter effects, 722(ab)
lymphoscintigraphy, malignant melanoma,
34
preparative regimen, bone marrow transplant,
692(ab)
radioimmunotherapy with, mammary
carcinoma xenografts, 573(ab)
recurrences of gynecologic carcinomas, 1807
renal cell carcinoma, phase I-II trials, 603(ab)
Iodine-131 NP-59
Cushing's syndrome, abnormal adrenals in,
640(ab)
silent adrenal mass, 1401
uptake, nonhyperfunctioning adrenal mass,
640(ab)
Iodine-131 OIH, renal plasma flow measurement,
1393
Iodine-131 toluidine blue, superimposed,
preoperative parathyroid localization by,
298
Iodanolene, effects of position, I-125 uptake and,
heart, 571(ab)
Iodosamethane, myocardial blood flow agents,
725(ab)
Iodochloroform, scintigraphy, primary
aldosteronism and Cushing's syndrome,
640(ab)
Iodophenyl, conjugates, protein labeling, 560(ab)
Iodophenyl fatty acids, metabolic and kinetic
evaluation, isolated rat heart, 667(ab)
Iridium-191, osmium-191/iridium-191m
generator awarded orphan product grant,
N154
Ischemia
extremity uptake and, bone scanning, 108
treatment, left ventricular wall motion induced
by, radionuclide angiography, 1725
N-Isopropyl p-iodobenzamine, biodistribution,
antidopressant and narcoleptic drug effects,
354
Isotopes, stable, cells and tissues, nuclear reactions
and charged particle camera, 697(ab)

J
Jolat, infections, diagnosis by
radioimmunoscintigraphy, 585(ab)
Joint prosthesis, femoral component of hip, dual
isotope arthography, 565(ab)

K
Kanno-Lassen algorithm
brain regional cerebral blood flow, 262(ab)
estimation of cerebral blood flow, from
tomographic-difficult tracer clearance curves,
407(ab)
Kato, Sadatade, Sadatade Kato honored with
service award from Radiopharmaceutical
Science Council, N150
Kawasaki disease, children, tomographic
myocardial perfusion scintigraphy, 1839
Kidney
allografts, evaluation of cold-storage and
immunosuppression, cortical perfusion
index, 731(ab)
amyloidosis, Tc-99m DMSA in, 734(ab)
arteriosus transit times, technetium-
radiolaabeled chelates, 1134
artery stenosis, MRI, angiography, and nuclear
medicine, 736(ab)
baseline function, renographic response to
captopril and, 612(ab)
blood clearance, Tc-99m DTPA uptake in bone
and, 1461
blood flow. See Blood flow
flow cell line, diphenylphosphates and polyphosphates
on phosphate transport, 602(ab)
depth determination, Tonnessen formula vs.
superfusion, 647(ab)
differential function, rapid method for
measurement, 829
disease
captopril effects on renography, 613(ab)
effective renal plasma flow, 622(ab)
Ga-67 scintigraphy in, 732(ab)
Tc-99m and captopril studies, 613(ab)
dynamic DTPA scan, evaluation of renal
excretion, 733(ab)
failure, Tc-99m MAG-3 kit formulation,
647(ab)
function
early and late changes, after nephrectomy,
735(ab)
renovascular hypertension or urinary
obstruction, 1-131 hipuran evaluation,
731(ab)
Tc-99m DTPA, aluminemic disturbance, 383
functional oncocytes, dual tracer
scintigraphy, 1911
glomerular filtration rate, three-hour volume of
distribution method, 510
hypertension, exchangeable sodium and body
fluid spaces, 733(ab)
In-111 F(ab)'2 distribution, normal mice,
692(ab)
In-111 Fab uptake, reduction of, 714(ab)
intravascular pressure effects, GFR, 716(ab)
kine driven function analysis, MRI, 703(ab)
plasma flow, 1-131 OIH measurement of, 1393
potential imaging agent, Tc-99m MAG-3
prolonged maintenance hemodialysis, bone
mineral content determination, 630(ab)
quantitative regional functional imaging,
732(ab)
routine work, Tc-99m MAG-3 and I-131
comparison, 647(ab)
silent damage, vesicoureteral reflux, siblings,
621(ab)

L
Lactate, infusion, myocardial ischemia, labeled
free fatty acid scintigraphy, 567(ab)
Laplacian-of-the-Gaussian, edge detection, image
reconstruction, 682(ab)
Lead-203, labeling, preliminary results, 721(ab)
Lead-203 DDC, measurement, brain perfusion,
mice, 723(ab)
LeBel, Etiene, Etiene LeBel recognized for
leadership in Canadian nuclear medicine,
NT91
Left bundle branch block, LAD disease with, TL-
201 SPECT in, 589(ab)
Lesions, space-occupying, calculations in feature
evaluation, 927(le)
Leskeniia, hairy cell, marrow involvement in,
NMR, 690(ab)
Leukocytes
albumin colloid, Tc-99m, characteristics,
574(ab)
labeling, Tc-99m tin colloids, 1471
Liability, Commentary: How the malpractice
crisis effects nuclear medicine physicians,
N1517
Lipophilicity, cerebral retention and, 729(ab)
Lipoproteins, metabolism, 1-123-LDL, 717(ab)
Lipoprotein receptors
low density
activity with Tc-99m LDL, liver, 610(ab)
uptake in liposome tissue, In-111 troplone
and, 610(ab)
Liposomes, In-111 cations, ionophoric transport,
91
Liver
angiography, portal venous hot spot,
689(ab)
arterial perfusion chemotherapy, Tc-99m MMA
imaging, 411(ab)
blood flow. See Blood flow
Budd-Chiari syndrome, typical and atypical
fundamental aspects, 803
Fc-receptor function, pre-and post-treatment,
690(ab)
fundamental reserve, estimation with Tc-99m
Liver-spleen scans

NGA, 627(ab)
hemangioma
MRI and Tc-99m RBC evaluation, 1683
Tc-99m RBC evaluation, infants and children, 1412
hemangioma and carcinoma, differentiation by SPECT, 688(ab)
hepatobiliary SPECT, deconvolution analysis, 689(ab)
hepatoma
I-131 lipiodol treatment, 707(ab)
I-125 PHT, 628(ab)
diWelling cancer, drainage patterns, hepatobiliary imaging, 1055
In-111 entrapment, proteins labeled using bifunctional chelates, 657(ab)
In-111 uptake, 264(ab)
localization of In-111, melanoma, 651(ab)
metastases, regional chemotheraphy and immunoscintigraphy, 706(ab)
parenchymal and nonparenchymal cells, radiolabeled monoclonal antibody uptake, 573(ab)
portal hypertension, portosystemic collaterals, blood-pool emission CT, 627(ab)
radiocolloid examination, detection of bone marrow metastases and, 184, 1640(ab)
radiolabeled monoclonal antibody metabolism, methods for study, 390
ratio of Tc-99m sulfur colloid, transaxial SPECT images, 675(ab)
septo-optic dysplasia, neonatal jaundice, 566
steatosis, kwashiorkor, Xe-133 uptake and, 622(ab)
tertiary syphilis involving, radionucleic imaging in, 1047
transplant, HIDA studies, tracer-kinetic modeling, 653(ab)
tumor blood flow, intra-arterial epinephrine, SPECT, 659(ab)
tumor necrosis factor, radiolabeled metabolic probes in, 640(ab)
tumors, Y-90, 708(ab)
visualization, I-131 whole-body thyroid scans, 1408
Liver-spleen scans, AIDS patients, 1792(ab)
Longitudinal emision tomography, two devices for, thyroid, 1892
Los Alamos National Laboratory
Los Alamos, conflict between radioisotopes and neutrinos resolved, N1378
physics experiment may cloud future of Los Alamos nuclear medicine program, proposals for dedicated radionuclide production facility, N1371
Lumped constant, deoxyglucose model, estimate, 471
Lung
asbestosis, Ga-67 emission tomography, 718(ab)
asymptomatic pulmonary embolism, following knee replacement, 584(ab)
cancer
In-111 anti-CEA localization, 615(ab)
soft-tissue accumulation of bone agent in, 1275
Ga-67 chest scans, AIDS, 1107
heart transplant and, tracheobronchial ciliary function in, 616(ab)
idiopathic fibrosis, In-111 leukocyte diagnosis, 616(ab)
I-131 HIPDM uptake model, 203
single-pass multiple indicator dilution technique, rabbit model, 487
M
Mallintyre, William J., William J. Mallintyre receives Aebersold Award for outstanding achievement in basic science applied to nuclear medicine, N795
Magnetic resonance imaging. See Nuclear magnetic resonance
Magnetopharmaceutical, kinetic function analyses, MRI, 703(ab)
Malpractice Insurance, Commentary: How the malpractice crisis effects nuclear medicine physicians, N1517
Manganese-54 DTPA, Gd-153 DTPA comparison, biodistribution, 349
Manic-depressive illness, D2 dopamine receptors in, 611(ab)
Marketing
advanced techniques, 1786(ab)
Nuclear Medicine Week, how it was observed in 1986, plans for 1987, N418
Medical economics, current and future trends, 1787(ab)
Medicare
bone densitometry asserts clinical role despite lack of reimbursement, N267
OHTA advises HCFA to deny Medicare coverage for SPA, DPA, N1656
Medullary carcinoma
thyroid
I-131 MIBG imaging, 576(ab), 1820
I-131 MIBG use in, 576(ab)
spinal bone mineral density in, 685(ab)
Melanosis, PET, development of tracers for, 701(ab)
Melanoma
detection
Ga-67 versus In-111 monoclonal antibody, 1441
In-111 monoclonal antibody, 1063(le)
Ga-67 uptake
anti-human transferrin receptor monoclonal antibody effects, 603(ab)
inhibition by anti-human transferrin receptor monoclonal antibody, 1303
lymphoscintigraphy, monoclonal antibody cocktail, 713(ab)
malignant
augmented splenic radicocolloid uptake in, 262(ab)
I-123 IMP, 562(ab)
nude rat transplanted with, radiolabeled monoclonal antibodies, 710(ab)
metastasis
imaging with Tc-99m antibody, 573(ab)
In-111 monoclonal antibody localization, 651(ab)
Tc-99m monoclonal antibody imaging, 650(ab)
monoclonal antibody lymphoscintigraphy, 34
ocular, radiolabeled, 637(ab)
radiolabeled monoclonal antibodies in, differential localization, 709(ab)
Metallobenezylguanidines
adrenergic nervous system integrity, 1620
adrenergic nervous system mapping, 1625
Metastatic disease, skeletal tuberculosis resembling, 1507(le)
Methotrexate, high dose, Tc-99m MDT and, diffuse hepatic uptake, 532
H3-N-Methyllepipерone, binding, serotonin-2 receptors, monoamine oxidase inhibitors and, 700(ab)
Metoclopramide
esophageal stimulation, progressive systemic sclerosis, 810
gastric emptying, systemic sclerosis, 688(ab)
misspelling, 1640(le)
Micrometastases, radioimmunotherapy, tumor spheroid model, 626(ab)
Misseadistrations, clarifying new misadministration reporting rules, N153
Misonidazole, imaging of hypoxia, 68
Modeling
componental antibody dosimetry, 617(ab)
linear and nonlinear, computer simulations, 653(ab)
neuroblastoma

nephrectomy, naltrexone, nebulizer, narcotic

1958

myocardium

C-11 BMHIDE synthesis, biological evaluation and, 728(ab)
contractility, radionuclide assessment, 578(ab) damaged
gd-159 edtgp localization in, 722(ab), 729(ab)
1-11 antimony in fab and tc-99m pyrophosphate, 76
extraction of i-133 ippa, cardiomyopathy, 670(ab)
fatty acid metabolism, i-123 ha, 924-926(le)
free fatty acid extraction, hypertensive heart disease, 567(ab)
function, coronary artery bypass surgery effects, 179(ab)
gd-dtpa as a perfusion agent, 871
glucose utilization, fdg and high resolution pet, 588(ab)
i-125 hbaa evaluation in, 667(ab)
imaging, tc-99m cpi, 13
i-123 mbg washout, sympathetic innervation and, 608(ab)
ischemia, short- and long-lived rubidium tracers for study, 989
lipid metabolism, 3-methyl-branching effects, 720(ab), 724(ab)
perfused beating, quantification of granulocyte infiltration, 667(ab)
perfusion and metabolism, after coronary thrombolyis, pet, 1563
quantitative imaging, tc-99m mibi compared with ti-201, 653(ab)
rotational ti-201 tomograms, quantification of, 673(ab)

rp-30 regional distribution, animal models of ischemia and reperfusion, 620(ab)
stunned canine, prolonged metabolic abnormalities, 558(ab)
tc-99m cations as perfusion agents, 149
there were 9-133 mibi and ti-201 uptake, comparison, cells, 667(ab)
ti-201 rotational tomography, evaluation of patients without infarction, 588(ab)
uptake of tc-99m r-p-30 vs. ti-201, workload effects, 666(ab)
wall thickening gated perfusion imaging, 618(ab)
ti-201 spect quantitation, 577(ab)

myoglobin, screening test, myocardial infarction, 568(ab)
myopathy, metabolism, p-31 mri, 598(ab)

n
naltrexone, oral, duration of opiate receptor occupation and, 612(ab)
narcotic drugs, distribution of imp and, 354
nebaltizer, tc-99m dtpa, chemical breakdown of, 378
nephrectomy, kidney function changes after, early and, 1735(ab)
neuromytic cyst, tc-99m pertechnetate diagnosis of, 1218

neuroblastoma

advanced, i-131 mibi therapy, 626(ab)
ganglioside g,

mouse, problem for i-131 mibi studies, 255(le)
radioimmunotherapy, tumor spheroids, 626(ab)
treatment with i-131 mibi, 627(ab)

neuroendocrine tumors, i-131 mibi scintigraphy in, 979
neuroreceptors, imaging, diagnosis and therapy, 1786(ab)
neutrinos, los alamos, conflict between radioisotopes and neutrinos resolved, n1378

newswire, commentary: newswire begins third year in jnm, n148

nitrogen-13

l-glutamate, metabolic fate in transplantable tumors, 594(ab)
pet, regional pulmonary ventilation, 587(ab)
stress ammonia pet imaging, ti-201 comparison, myocardial ischemia, 567(ab)

nitrogen-13 am-67, myocardial perfusion reserve, changes after ptca, 1262
nitroprusside, exosimine comparison, ventricular volume, 669(ab)
nitroreductase, synthesis, brain tumor, 625(ab)
nmr. see nuclear magnetic resonance

nomenclature, nomenclature committee seeks input on cpt-4, n802
nerepineshrine, i-125 mibi and, adrenomedullary cells, 639(ab)

nuclear accidents

see also chernobyl

cbernobyl, physicians' role examined in planning response to nuclear accidents, n413
uptake of different radionuclides, chernobyl accident, southern sweden, 581(ab)

nuclear magnetic resonance

acute myocardial infarction, comparison with in-111 antimony imaging, 590(ab)
adrenoleukodystrophy, 524

acetic ncssosis, femoral head, 564(ab)
cardiac functional display, 705(ab)
geometrical and functional, 590(ab)
contrast agents, gd-153 dtpa and mn-54 dtpa comparison, 349

correlation, renal allograft assessment, 733(ab)
detection of fluoride, bone, 703(ab)
5-fluorouracil and, drug metabolism, 599(ab)

gd-67 and, aortic root abscess, 1616
gaiting, 545(Le)
gd-based, endogenously available ions, 705(ab)
gd-dtpa, myocardial perfusion agent, 871

cancer, marrow involvement, 690
hepatic hemisphere evaluation, 1683
hepatabiliary enhancement, fe-hbed and fe-ehpg, 590(ab)

high-resolution, spect comparison, temporomandibular joint, 1268
localization of gd-159 edtgp, damaged rat myocardium, 722(ab), 729(ab)
myocardial infarction, ischemia and, segment comparison, 260(ab)

myocardium

phosphonate complexes of gadolinium, 260(ab)
phosphonate complexes of gd, 406(ab)

new lesion phantom, 590(ab)
p-31

breast, 599(ab)

metabolism of myopathies, 598(ab)
regional signal suppression, 599(ab)
pleocromocytoma detection, 639(ab)
potential pitfalls, avascular necrosis diagnosis, 1052

recombinant tissue plasminogen activator, acute myocardial infarction, 591(ab)

rn correlation, nodular thyroid disease, 685(ab)
sclerosis, 704(ab)
skeletal, endocrine, and cardiovascular systems, 1786(ab)
slice profile, averaging error in, 705(ab)
spinal lesions, comparison with bone scintigraphy, 590(ab)

stereotactic method comparison, brain structures on o-15-h2o pet scans, 702(ab)
tc-99m mdma scintigraphy and, acute hydrocephalus, pgi, 59(ab)
tc-99m pyfp biodistribution, myocardial infarction imaging, 704(ab)

three dimensional correlations, pet and ct, 682(ab)
thyroid and parathyroid, 122

ti-201 and, myocardial ischemia and infarction by, 703(ab)

nuclear magnetic resonance (nmr) council, snm petitions for new councils: nmr and commercial services, n801

nuclear medicine history

etienne lebel recognized for leadership in canadian nuclear medicine, n791
eugene l. saenger honored with snm hevesy nuclear pioneer award, n793
maleah grover-mckay receives tetalman memorial award, n1100
marshall brucer still full of acerb wit 30 years after serving as snm president, fight against societal radiation phobia, n1645

nuclear medicine as a practical medical science, n1647
william j. macintyre receives aebersold award for outstanding achievement in basic science applied to nuclear medicine, n795

nuclear medicine practice

automated cost accounting and billing program, 265(ab)

commentary: how the malpractice crisis affects nuclear medicine physicians, n1517

commentary: lines from the president—radiodiagnostics, drugs, and the fda, n1804
commentary: lines from the president—protecting "window of expectancy", n1381

commentary: who speaks for nuclear medicine?, n942
departmental quality assurance program, 679(ab)
purchase equipment decisions, based on clinical needs and facility design, transition from planar to spect, pet, n278

harvard omits nuclear medicine from relative value scale study, n1250

nomenclature committee seeks input on cpt-4, n802

nrc removes nuclear physicians from hospital licenses for falsifying records, proposes new rules for quality assurance, training and experience, n1653

proposal for physician fees paid by drg system for radiology, anesthesiology, pathology (rap-drgs), n149

rap-drgs defeated in congress, rvs to be developed for radiologic services, n1513

snm board of trustees adopts statement on credentialing and delineation of privileges, snm urges us congress to require peer review for research grants, n1651

snm members, focus groups, n1248
Positron labeled antibodies

C-11 eticlopride, synthesis, 625(ab)
C-11 L-methionine accumulation and, brain, 645(ab)
C-11 methyl iodide synthesis, origin of carrier in, 728(ab)
C-11 nitromethane, use as a radiolabeling nucleophile, 636(ab)
C-11 NMKET and, localization of serotonin-2 receptors, 600(ab)
C-11 pyrimidine, synthesis and biodistribution, 624(ab)
C-11 thymidine, development as an imaging agent, 728(ab)
cerebral blood flow agents for measurement, 134(le) defects in chronic cocaine users, 655(ab) pre-operative mapping of critical function, 646(ab) stroboscopic stimulation, 702(ab)
cerebral malignancy, 1251 cerebral protein synthesis, C-11 leucine, 587(ab) clinical scanning, 1789(ab)
CMR02 measurement by, oxygen-15 bolus model, 699(ab)
comparison with angiography, exercise ability and, 626(ab) complex partial epilepsy, comparative investigation, 702(ab) constrained least squares filtering technique, image count density dependence, 661(ab)
copper radiopharmaceuticals brain and heart, 407(ab) cerebral blood flow measurement, 722(ab) cortical and subcortical metabolism, anxiety effects, normals and schizophrenia, 655(ab)
D2 dopamine receptor measurement, primates, 611(ab)
depth-of-internalization of radiolabeled crystals, temperature gradient, 641(ab) dosimetry estimates for, C-11 labeled thymidine, 683(ab)
end-capillary oxygen pressure, measurement of, 656(ab) equipment purchasing decisions, based on clinical needs and facility design, transition from planar to SPECT, PET, N278 FDA efforts to reduce radiopharmaceutical review time, advisory committee discusses regulation of PET products, N1
F-18 deoxyglucose cerebral glucose metabolism, 53, 1667 myocardial glucose uptake, dopamine effects, 668(ab) rate constants, myocardium, 682(ab)
F-18 DGAL, hepatocellular carcinoma, 706(ab)
F-18 estradiol, assessment of estrogen receptors in breast cancer, 561(ab)
F-18 FDG brain tumors, 594(ab) malignant gliomas, 645(ab)
F-18 fluorocarboxylic acid ester, 634(ab)
F-18 fluorodeoxyglucose, regionselective fluorodecomposition, 624(ab)
F-18 fluoromisonidazole, F-18 fluoromisonidazole, 594(ab)
F-18 labeling of proteins, 462
F-18 progesterone distribution, animal studies, 625(ab) functional mapping of FDG rate constants, Alzheimer’s disease, 699(ab)
Ga-68 transferrin, measurement of pulmonary vascular permeability, 1704 glioma evaluation with, 1123 glucose metabolism and DNA polymorphism studies, Huntington’s disease, 655(ab) high resolution brain, 608(ab) comparison of images from two, 608(ab) count rate capability and dead time, 607(ab) heart, attenuation correction, 696(ab) myocardial glucose utilization, 588(ab) Scintorionix PC1024-7B scanner, 607(ab) stationary-sampling, 607(ab)
ischemic penumbra, evolution with time, 633(ab) large hot and cold spheres, unique phantom, 696(ab) LCBF measurements, human data, 587(ab) local cerebral blood flow studies, 1695 maximum-likelihood reconstruction, noise and edge artifacts, 566(ab) melanin imaging, development of tracers for, 701(ab) Monte-Carlo simulation, scatter deconvolution technique, 681(ab) myocardial blood flow measurement, hypertrophic cardiomyopathy, N-13 ammonia, 657(ab) myocardial perfusion and metabolism, after coronary thrombolysis, 1563 myocardial perfusion reserve, changes after PTCA, 1262 n-aloxone preloading effects, opiate antagonist F-18 CF, 701(ab)
N-13 and, regional pulmonary ventilation, 587(ab)
neuro, F-18 fluoroprednisone synthesis and evaluation, 998 new whole-body system, 641(ab) nuclides, formation of target species during, 634(ab) opiate receptors, C-11 diprenorphine for, 635(ab) oxygen-15 carbon dioxide, radiation dose to upper airways from, 234 parameters estimated with, bias and covariance in, 682(ab) perfusion imaging, 410(ab) photons/RAD ratios, tracer labels, 683(ab) positron-emitting radiopharmaceuticals for, robot for production, 727(ab) primary lung cancer, C-11 methionine uptake and, 658(ab) quantitation in, radon transform distortions, 641(ab) radiobrominated phosphonium cations, high myocardial specificity, 726(ab) radiolabeled palmitate, myocardial ischemia, 1322 radiolabeled-neuropeptide interaction, four-compartment model, 681(ab) refractory neonatal seizures, surgical selection, 646(ab) rubidium, transient ischemia, 989 sinograms, missing data, 565(ab) “slices of life,” scientific highlights, SNM 34th Annual Meeting, 1987, N1235 SNM/ACNP symposium on PET/SPECT for practitioners, N944 steady-state, regional cerebral blood flow, unstimulated 14 minute period, 700(ab) structural and functional images, correlation in same patient, 634(ab) study of two behavior states, 852 systematic errors in, selecting contrast phantoms, 698(ab) temporal lobe epilepsy, regional opiate receptors and glucose utilization, 699(ab) test-retest paradigms, errors from subject repositioning, 681(ab) three dimensional correlations CT and MRI, 682(ab) treatment of axial data, 1717 thymidine nucleotides, cellular sources for, 1435 time-of-flight, performance measurements of, 696(ab) tissue O-15 oxygen kinetics in, oxygen utilization rate in, 631(ab) validation of input functions, RB-82 cardiac studies, 621(ab) V-48 vanadyl(IV)-phosphoramide, cancer diagnosis, 723(ab), 727(ab)
Positron labeled antibodies, parathyroid specific, evaluation, 582(ab)
Postprandial blush, multiphase bone scanning, 1550 Pregnancy, radionuclide venography in, 1290 Preleukemia, following large dose radiodiode therapy, metastatic thyroid carcinoma, 1348 Pressure-volume relations, ventricular suction measurements by, 557(ab) Price-Anderson Act, nuclear medicine, pharmacies, seek indemnification, Price-Anderson Act, N1382 Probabilistic image, regional wall motion abnormalities, 676(ab)
Proctography balloon, assessment of anorectal angle, 550(ab) scintigraphic balloon, anorectal angle, 660(ab) Profile analysis, assessment of organ dimensions, 551(ab)
Progesterone, gastric emptying and, 1204 Prospective Payment System (PPS) Commentary: lines from the president — protecting "window of expectation", N1381 proposal for physician fees paid by DRG system for radiology, anesthesiology, pathology (RAP-DRG), N149 RAP-DRGs defeated in Congress, RVS to be developed for radiologic services, N1513 Prostate, SR-89 therapy, between patient variation in streptomycin kinetics, 683(ab)
Prostheses infected, In-111 chloride imaging of, 255(le) orthopedic, suspected infection, In-111 WBC in, 586(ab)
Protein labeling 4-1000-benzoates for, 725(ab) iodophenyl conjugates for, 560(ab) radiolabeling of, increased retention of label, 725(ab)
Pulmonary edema, vascular permeability in, PET and Ga-68 transferrin measurements, 1704 Pulmonary embolism asymptomatic, following knee replacement, 584(ab) clot localization in, non-platelet bound antibody, 718(ab) experimental detection, antibody imaging, 584(ab) In-111 and In-125 anti-platelet antibody behavior, 720(ab) lung scanning computer assistance, 584(ab) cost-effectiveness and benefit-risk, 1521 ventilation-perfusion scan, digital subtraction angiography compared with, 564(ab)
Pituitary, PET studies, cerebral malignancy, 1251
Radioligands

different, uptake from Chernobyl accident in southern Sweden, 581(ab)
dose rate effects, 617(ab)
postion emitting, scintillation well-counting of blood samples, 697(ab)

Radiochemicals

aerosolized, respiratory clearance of, 894 antibody, serum stability of radioconjugates for, 83 copper, PET with, brain and heart, 407(ab) heart, chemistry of, 1351

in vivo evaluation, factor analysis for, 680(ab) postion-emitting, for PET, robot for production, 727(ab)
receptor-binding, 653(ab)

Radiochemical science, Committee on Nuclear and Radiochemistry explores nuclear medicine issues, training requirements for nuclear medicine chemists, N1519

Radioisotope safety

Chernobyl, decontaminate world threatened by fallout, risk misperception, N933
Chernobyl, physicians' role examined in planning response to nuclear accidents, N413

Commentary: Chernobyl predictions and the Chinese contribution, long-term health effects, N423
nuclear medicine community responds to EPA guidelines for indoor radon levels, cost/ benefit analysis, epidemiologic studies, N1087
radon gas, radon daughters, pose potential environmental hazard, linked to lung cancer, N1095

Radiation safety

California researchers escape criminal charges for radiation safety violations, N1655
Guidelines for radiation safety, AIDS prevention, pose conflict, N1806
NRC removes nuclear physicians from hospital licenses for falsifying records, proposes new rules for quality assurance, training and experience, N1653

Radioactive waste, low-level, Cal Rad Forum, workshop, low-level radioactive waste, N1382

Radioactivity, monitoring after I-131 therapy, 106(46)

Radar

cutoff of RIA, discordant inter-kkt results, 71(ab) CX-BB levels, intracranial hemorrhage, premature infant, 71(ab)
commercial kit, calcitonin stability and, 71(ab) mental, SQ 27,519 in human serum, 56(ab)
measurement of thyroglobulin, differentiated thyroid carcinoma, 68(ab)
radioreceptor assay and, comparison of cholecystokin analogues, 56(ab)
RIA cost-effectiveness study moves ahead, N430 T4-analog/albumin, binding in analog T4 assays, chemical inhibition, 569(ab) thyroxine binding globulin, free thyroxine index, normal, thyroid disease, and sick euthyroid patients, 1341
TSH kit, simultaneous free T4 and, 71(ab)

Radioimmunoassay

anti-monoclonal antibodies, cancer, 652(ab) I-123 anti-granulocytes antibodies, infectious lesions, 614(ab)
In-111 fab'2 distribution, normal mice, 692(ab)
In-111-hapten-monoclonal antibody normal mice, 692(ab) nude mouse-human colon tumor model, 711(ab)

initial studies, monoclonal antibodies recognizing colon cancer, 713(ab)
testicular cancer xenograft, athymic mice, IgM monoclonal antibody, 71(ab)

Radioimmunoscintigraphy

absorbed dose to patient, 617(ab) chelation of In-111 to monoclonal antibodies, colon carcinoma xenografts on athymic mice, 861
diagnosis of bone and joint infections, 585(ab) DTPA, efficient coagulation to IgM monoclonal antibody in ascites fluid, 693
ocular melanomas, 637(ab) regional chemotherapy and, liver metastases, 70(ab)
uptake of In-111 anti-CEA, colorectal cancer, 637(ab)

Radioimmunotherapy

curative adjuvant, treatment planning, 617(ab) cutaneous T-cell lymphoma, 553(ab) retreatment, plasmapheresis effects, 603(ab) DTPA, efficient coagulation to IgM monoclonal antibody in ascites fluid, 693
generator-produced Yttrium-90, 1465 hama-murine antibody complexes, 614(ab) immunotherapy comparison, animal model, 691
labeling of Rhenium-186 antibodies for, 656(ab) quantitative autoradiography, micro-TLD measurements and, 617(ab)
Y-90 biodistribution in patients, 712(ab)

Radioisotopes, In-111 and I-131 monoclonal antibodies, biodistribution, 722(ab)

Radioiodine

dose evaluation, newborn, 1208 nasal uptake, 686(ab)
Radioisotopic precursor, C-11 nitromethane, 636(ab)
Radioimmunoglobulins, receptor-binding, estimation of hepatic functional reserve, 627(ab)

Radioimmunoassay, C-11 nitromethane, 63(ab)

Radioiodide

dose evaluation, newborn, 1208 nasal uptake, 686(ab)
Radioguided, C-11 iodine, 636(ab)

Radioimmunoassay

cortiogonadotropin, discordant inter-kkt results, 71(ab)

Regional wall motion

detection of abnormalities, probabilistic image, 676(ab)
perfusion defects and extent of ischemia, thallium scintigraphy, 598(ab)
Relative value scale (RVS) payment system

Relative value scale (RVS) payment system, Harvard omits nuclear medicine from relative value scale study, N1250

Renal artery
flow defects, radionuclide angiography and renography, 613(ab)
stenosis, MRI, angiography, and nuclear medicine, 736(ab)

Renal calculi, pre- and post-extracorporeal shock wave lithotripsy, radionuclide evaluation, 1284

Renal cell carcinoma
phase I-II trials, I-131 monoclonal antibody, 603(ab)
 xenografts, I-131 monoclonal antibody immunonuclide therapy, 651(ab)

Renography
captopril
Goldblatt hypertension, 1171
renovascular hypertension, 613(ab), 735(ab), 1338
radiouclide, plasma time-activity curve during, 1338
radiouclide angiography and, renal artery flow defects, 613(ab)
Tc-99m DTPA, glomerular filtration rate measurement, 399(ab)

Research funding
E&R Foundation, student fellowships, N1250
E&R Foundation plans permanent endowment, N801
SNM testifies in Congress on DOE research funding, DOE offers grants for epidemiologic studies, N1249
Respiratory clearance, aerosolized radioactive solutes, varying molecular weight, 894

Reticuloendothelial system, function, critical colloidal dose studies in, 1424

Rervascularization therapy, renovascular hypertension, 406(ab)
Rhenium-186 antibodies, labeling for radioimmunotherapy, 656(ab)
Rhenium-188, improved generator, radiotherapy cocktails, 656(ab), 657(ab)
Rheumatic disorders, bone scanning in, 262(ab)
Ribbing’s disease, Engelmann’s disease comparison, 245

Risk perception. See Chernobyl; Radon

Rotating display, subjective characteristics of, 678(ab)

Rubidium, short- and long-lived tracers, transient ischemia, 989
Rubidium-82, skeletal muscle blood flow, glucose, insulin, and exercise effects, 1155
Rubidium-83, myocardial uptake, alterations in perfusion and oxygenation, heart, 878
Rubidium-86, cardiac transport, hypoxia and, 620(ab)
Rubidium-86 chloride, metabolic marker, brain tumor response to chemotherapy, 595(ab)

Ruthenium-97 DISIDA, duodenogastric reflux, gastric emptying and, 596(ab)

S

Saenger, Eugene L., Eugene L. Saenger honored with SNM Hevesy Nuclear Pioneer Award, N793

Sagittal transverse slices, visualization, scintigraphic evaluation of brain death, 1279

Samarium-153 chelates, skeletal localization, 495
Samarium-153 EDTMP, injections, radiation dose calculations, 505

Sarcoldosa, childhood value of Ga-67 in, 716(ab)
Sarcoma, osteogenic, xenografts, In-111 monoclonal antibody localization of, 342

Scatter deconvolution technique, PET, Monte-Carlo simulation, 681(ab)
Schizophrenia
on and off medication, cerebral glucose consumption, 702(ab)
regional cerebral blood flow measurements, and camera head tilt, 1592

Sclerodermia
camera
dual-photon absorptiometry, spine, 665(ab)
F-18 FDG, imaging of thyroid carcinoma, 910
para-axial neufibromatosis, 1688
quality assurance manual for, N154
Wada test, epileptic patients before and during Wada test, 1763
Sclerostin crystals, depth-of-interaction, determination with a temperature gradient, 641(ab)
Sclerostin well-counting, blood samples, positron emitting radionuclides, 697(ab)

Sclerosis
hepatobiliary imaging in, gastroesophageal reflux, 387
metacalopamide esophageal stimulation, scintigra phy detection, 810

Semenoma, immunocytoassay for chorionicadotropin, discordant inter-kit results, 719(ab)

Serotonin
receptors
equilibrium binding kinetics, brain, 611(ab)
irreversible agonist, CNS, 725(ab)
Serotonin-2 receptors, localization, C-11 NMKET, 600(ab)

Sex differences, TI-201 SPECT, bullseye display, 642(ab)

Single-photon absorptiometry (SPA)
See also Absorptiometry
bone densitometry asserts clinical role despite lack of reimbursement, N267
OHTA advises HCFA to deny Medicare coverage for SPA, DPA, N1656
osteoarthritic fractures of spine and distal forearm, 960

Single-photon emission computed tomography (SPECT)
acceptance testing, quality control and, 1221
angio graphic sampling, 1308
aneurysm necrosis, femoral head, 564(ab)
atlas image analysis in, 577(ab)
attenuation correction equation, 1925(ab)
simultaneous transmission and emission tomography, 677(ab)
blood flow measurements, regional cerebral, schizophrenia, 698(ab)
bone grafts, therapeutic evaluation of, 564(ab)
brain delayed scan with I-123 IMP, 559(ab)
  xenon-133 and I-123, 570(ab)
  Tc-99m HM-PAO, 1657
brain perfusion, Tc-99m HM-PAO, 569(ab)
C-11 and I-125 IBZ, D2 dopamine receptor imaging, 726(ab)
cerebral blood flow arteriosclerotic malformations, 591(ab)
I-123 IMP brain imaging, 570(ab)
I-123 IMP tracer kinetics for measurement, 569(ab)
infarct hyperemia, Tc-99m HM-PAO, 633(ab)
measurement with I-123 IMP, 558(ab)
surgical stroke, SPECT, 699(ab)
Tc-99m, Wada test and, 592(ab)

To-99m HM-PAO, 559(ab)
transient ischemic attacks, 633(ab)
cerebral perfusion imaging, 1364(ab)
clinical images, nonuniform attenuation correction improvement of, 661(ab)
collimators, measurement of plate angulation and camera head tilt, 1592
compensation for attenuation, tumor activity, 577(ab)
cornea detector system, estimating parameters of, 661(ab)
3-D, cone beam collimation, 678(ab)
defect detectability, modified Iowa heart phantom, 643(ab)
epinephrine, intra-arterial infusion, hepatic tumor blood flow, 659(ab)
equipment purchasing decision, based on clinical needs and facility design, transition from planar to SPECT, PET, N278
fan beam collimation, high resolution I-123 HIPDM brain imaging, 570(ab)
femoral head, following acetabular fracture, 664(ab)
fILTERING and scatter correction, 410(ab)
functional thyroid volume determination, 575(ab)
Ga-67, asbestosis, 718(ab)
gamma camera based systems, noise characteristics, 696(ab)
gated cardiac blood-pool scanning problem in data sampling, 668(ab)
regurgitant fraction of left ventricle, 19
hepatic hemangioma, differentiation from hepatocellular carcinoma, 688(ab)
hepatobiliary, deconvolution analysis, 689(ab)
high resolution, 409(ab)
astigmatic collimator, brain, 576(ab)
cornea beam collimator, brain, 577(ab)
fan beam collimator, brain, 576(ab)
high-resolution MRI comparison, temporomandibular joint, 1268
HIPDM, radioactive iodine exchange reaction, 360
I-123 HIPDM, complex partial seizure foci, 600(ab)
I-123 IMP distribution, temporal changes in, brain, 623(ab)
I-123 iodomepapertine cardiovascular disease, 622(ab)
regional cerebral blood flow, 619(ab)
I-123 MBG, after transmural myocardial infarction, dog model, 669(ab)
I-123 siperone, high-yield labeling, animal studies, 570(ab)
I-125 dimethyl fatty acids measurement of myocardial fatty acid uptake, 724(ab)
myocardial uptake and clearance kinetics of DMIPP analogues, 571(ab)
image interpretation, TI-201, feature extraction, 618(ab)
image reconstruction, detector responses in, 566(ab)

Improved, simultaneous emission and transmission tomography, 844
improved myocardial imaging, TI-201, energy weighted acquisition, 577(ab)
In-111, new collimator for, 696(ab)
In-111 anti-CEA monoclonal antibody, abdominal colorectal cancer, 604
In-111 leukocytes, inflammatory bowel disease diagnosis, 659(ab)
instrumentation and image processing techniques, 1788(ab)
thoracic and lumbar spine, suspected vertebral metastases, 665(ab)
three-dimensional, two-dimensional mapping, 405(ab)
three-dimensional spatially-variant point spread function, algorithm for compensation, 662(ab)
three-dimensional transfer function, filtered backprojection, 630(ab)

Sci-21
alterations in distribution, chronic hypertension, 673(ab)
bullseye display, sex differences, 642
dipyridamole with, coronary disease, 642(ab)
estimation of left ventricular mass, normal and infarcted heart, 1315
image artifacts that decrease specificity, 672(ab)
LAD disease with left bundle branch block, 589(ab)
left-ventricular aneurysm, 168
leg muscle perfusion, 717(ab)
measurement of ventricular mass, heart rate and contractility effects, 408(ab)
motion during, 642(ab)
myocardial, following dipyridamole for CAD, 408(ab)
myocardial infarct size, 325
oral dipyridamole and, CAD, 579(ab)
patient and cardiac movement in exercise, 630(ab)
peripheral arterial disease, leg, 717(ab)
quantitative analysis for myocardial images, 643(ab)
quantitative criteria to read defects, 674(ab)
stress-induced myocardial perfusion defects, 642(ab)

Sci-21 DDC, cerebral blood flow, 178
Sci-21 rotational, evaluation of coronary disease following MI, 674(ab)
transverse, pinhole collimator, 678(ab)
uniform attenuation in, convolution algorithm for, 677(ab)

Xe-133
cryptogenic West syndrome, 592(ab)
inhalation, demented patients, 599(ab)

S-153 EDTM
autoradiographic evaluation, radiotherapeutics for primary bone cancer, 709(ab)
ossous metastasis, 708(ab)

Society of Nuclear Medicine (SNM)
Commentary: assembling the SNM scientific program, N792
Commentary: lines from the president—
protecting “window of expectancy,” N1381
Commentary: lines from the president—SNM 1986–1987 year in review, N1099
Commentary: lines from the president—radiodiagnosis, drugs, and the FDA, N1804
Commentary: lines from the president—pragmatists prevail at Winter Meeting, N227

Commentary: Newsline begins third year, N148
Commentary: rationale for “SNM in Canada”, N10
Commentary: who speaks for nuclear medicine?, N942
E&R Foundation, student fellowships, N1250
E&R Foundation plans permanent endowment, N801
Ettiene LeBel recognized for leadership in Canadian nuclear medicine, N791

Eugene L. Saenger honored with SNM Hevesy Nuclear Pioneer Award, N793
FDA efforts to reduce radiopharmaceutical review time, advisory committee discusses regulation of PET products, N1
Maleah Grover-McKay receives Tetalman Memorial Award, N1100
Marshall Brucher still full of acerb wit 30 years after serving as SNM president, fight against societal radiation phobia, N1645
Nuclear Medicine Week, how it was observed in 1986, plans for 1987, N418
RIA cost-effectiveness study moves ahead, N430
Sadasuke Kato honored with service award from Radiopharmaceutical Science Council, N150
“slices of life,” scientific highlights, SNM 34th Annual Meeting, 1987, N1235
SNM/ACNP symposium on PET/SPECT for practitioners, N944
SNM Asia tours, two international nuclear medicine conferences in China, N1806
SNM Board of Trustees adopts statement on credentialing and delineation of privileges, SNM urges US Congress to require peer review for research grants, N1651
SNM Board of Trustees meeting, Brain Imaging Council, chapter representation, credentialing statement, N426
SNM Computer Council plans buyers’ guide, N154
SNM councils report at Winter Meeting, N802
SNM 1987 election results, N1250
SNM expands criteria for Berson-Yalow Award, N944
SNM Instrumentation Council promotes electronic mail, N1656
SNM issues first call for abstracts, 35th Annual Meeting, San Francisco, N1516
SNM members, focus groups, N1248
SNM members offered special enrollment for insurance plan, N1520
SNM petitions for new councils: NMR and Commercial Services, N801
SNM physician and scientist manpower survey, N430
SNM Technologist Section names Barbara Horton as distinguished honoree, National Council holds strategic planning session, N1652
SNM testifies on Congress of DOE research funding, DOE offers grants for epidemiologic studies, N1249
SNM 34th Annual Meeting, Toronto, Canada, N799
SNM Winter Meeting, perfusion imaging, N12
Technologist Section, National Council meeting, professional identity within allied health, N799
Technologist Section nominations for 1987 election, N430
William J. MacIntyre receives Aebersold Award for outstanding achievement in basic science applied to nuclear medicine, N795
SPECT. See Single-photon emission computed tomography
Splan bone mineral, loss with inactivity, 260(ab)
Splan cord injury
bone mineral loss in femur in, 1792(ab)
biliary kinetics, 688(ab)
gallbladder motility in, 596(ab)
Splan lesions, bone scintigraphy, comparison with NMR, 590(ab)

Subject Index • 1987

1963
Spine
lumbar, regional differences in mineral density, 663(ab)
upright, scintigraphy, 664(ab)

Spine
fluorooalkylated, cerebral D2 binding, 612(ab)
receptor-mediated endocytosis, 612(ab)

Spleen
augmented radiocolloid uptake, malignant
melanoma, 262(ab)
autologous implantation, splenosis
differentiation from, 638(ab)
blunt trauma, colloid shift following, 188
F-18 receptor function, pre- and post-treatment, 690(ab)
pancreas organ donation, artery and vein
resection for, Tc-99m, 638(ab)

Splenosis, differentiation from autologous spleen
implant, spleen scan, 638(ab)

Spondylitis, bacterial, early diagnosis with bone
scan, 254(ab)

Spondylosis, detection, planar and SPECT
scintigraphy, 665(ab)

Stemna, lesions, breast cancer, 606(ab)
Streptokinese, intravenous, treatment of
experimental frostbite, rabbit, 606(ab)

Strontium-89, metastatic bone pain and, 553(ab)

Subarachnoid hemorrhage, blood flow
abnormalities following, brain, 634(ab)

Sulfur colloid, Tc-99m, pancreatic allograft, 
583(ab)

Sympathetic nervous system, I-123 MIBG
imaging, idiopathic congenital
cardiomyopathy, 667(ab)

Syphillis, tertiary, liver and bones, radionuclide
imaging in, 1047

Systemic perfusion, method of uptake, 
radiolabeled monoclonal antibodies, 
715(ab)

T

Technetium, chemistry and design implications, 
593(ab)

Technetium-99m agents for brain scintigraphy, 1787(ab)
automated edge detection technique, intracranial thrombosis, 135(ab)
bolus first pass analysis, renal transplants and
penis, 406(ab)

bone scintigraphy, patellar tendinitis, 1768
cholocystokinin cholecintigraphy, gallbladder
contractility in fundal adenomyomatosis, 
1771

complexes comparison with Tl, myocardial perfusion, 
405(ab)
multiple small chain alkylated, 729(ab)
stereoisomers of, 601(ab)
dose calibrator response, varying geometry
effects, 1478

emissions in water, effective attenuation
coefficient for, 678(ab)

first pass analysis, renal blood flow, 403(ab)
isonitrile complexes, 602(ab)
labeling of platelets with, 26(ab)
leukocyte labelling, 1228(ab)
monitoring of lag phase, gastric emptying, 
563(ab)
normal complexes, synthesis, characterization, 
and reactivity, 728(ab)

perfusion-function imaging, CAD, 597(ab)

radiopharmaceutical preparation, surface
absorbed stannous ions, 1041
reference level, gastric emptying, 563(ab)
sцинтиграфский balloon protograph, anorectal
angle, 660(ab)
tin colloids, leukocyte labeling with, 1471
Tl-201, improvement in subtraction, nonlinear
regression transformation technique, 
687(ab)

tris 8-diketone complexes, synthesis and
biodistribution, 730(ab)

Technetium-99m albumin, first-pass anger camera
radiocardiography, ventricular ejection
fraction, 950

Technetium-99m albumin colloid, leukocyte
preparation, characteristics, 574(ab)

Technetium-99m antibody
blood clearance of, ester bonds and, 602(ab)
metastatic melanoma, known and occult, 
573(ab)

Technetium-99m BAT
brain perfusion imaging, SPECT, 1012
stereoisomers of, structure-biodistribution
relations, 1930(ab)

Technetium-99m cations, inorganic chemistry of, 
1491

Technetium-99m colloid, adverse reactions to, 
178(ab)

Technetium-99m CPI interspecies comparison of distribution, 601(ab)

myocardial imaging, 13

Technetium-99m DADT
chemical structure, accumulation and retention, 
brain, 594(ab)

complexes, pulmonary accumulation of, 729(ab)
site selective localization, brain hippocampus, 
rat, 731(ab)

Technetium-99m diphosphonates, phosphate
transport and, renal cell line, 602(ab)

Technetium-99m disofenin, biliary kinetics, spinal
cord injury, 638(ab)

Technetium-99m DMSA
clearance, renal amyloidosis, 734(ab)

imaging of medullary thyroid carcinoma, 
252(ab), 253(ab)

medullary carcinoma, thyroid, 56(ab)
MRI and, hemodynamic changes in 
hydropneumosis, pig, 598(ab)

Technetium-99m DTPA
aluminemic disturbance, renal function
measurement, 383

ANF effects, Goldblatt hypertension, 734(ab)
captopril renography, 733(ab)

chemical breakdown, during nebulization, 378
differential renal function, rapid method for
measurement, 829

distribution and relativity of Gd-153 chelates, 
mouse tumors, 705(ab)
dynamic scan deconvolution analysis application to, 
734(ab), 735(ab)

renal excretion evaluation, 733(ab)
enhanced by captopril, renovascular disease,
613(ab)

extrapulmonary radioactivity, lung permeability
measurements, 903

glomerular filtration rate measurement, 372,
510, 399(ab)
-labeled tablets, dissolution rate and transit

times, 1199

YPF comparison, lung imaging, 585(ab)
radiation absorbed dose from, 240

renal allograft assessment, MRI/RN correlation, 
733(ab)

renal blood flow, non-invasive measurement, 
646(ab)
single-dose captopril and, renovascular
hypertension, 1383

SPECT, para-axial neurofibrinomatosis, 1688
split renal function, renovascular hypertension
or urinary obstruction, 73(ab)

uptake, bone, blood clearance and, 1461

Technetium-99m GH, granulocyte labeling, 
690(ab)

Technetium-99m GH-SC, patterns, pancreatic
allograft, 583(ab)

Technetium-99m glucoheptonate, comparison with 
Ga-67 citrate, pulmonary malignancies, 
442

Technetium-99m HES, preparation and 
evaluation, lymphoscintigraphic agent, 
730(ab)

Technetium-99m HMDP, bone, early diagnosis of 
bacterial lymnar spondylitis, 254(ab)

Technetium-99m HM-PAO
brain scintigraphy, Huntington's disease, 
406(ab)

brain SPECT imaging, 569(ab)

comparative, I-123 amphetamines and, 
569(ab)

initial experience with, 1657

regional blood perfusion, 191

Wada test and, 592

cerebral blood flow, 407(ab)

compartmental model, 559(ab)

SPECT, 559(ab)

triple label digital autoradiography, 559(ab)
cerebral kinetics, first minutes after injection, 
baboon, 593(ab)
c

clinical use in adults and pediatric patients,
179(ab)

comparison with In-111, imaging inflammation, 
574(ab)

decomposition, aqueous media, 593(ab)

eye and, late SPECT, distribution in 
cerebrovascular disease, 59(ab)

evaluation, leukocyte labeling, 638(ab)

granulocyte labeling, 690(ab)

I-123 IMB SPECT and, subacute strokes, 
623(ab)

kinetic considerations, clinical evaluation and, 
701(ab)

labeled leukocytes, imaging inflammation with, 
648(ab)

metabolic marker, brain tumor response to 
chemotherapy, 595(ab)

mixed leukocytes with, clinical protocol for 
radioisotopic labeling, 694(ab)

RBC SPECT and, cerebrovascular disease, 
600(ab)

SPECT
acute cerebral infarction, 622(ab)

primary brain tumors, 591(ab)

vs, Tl-201 DDC, subcellular distribution, 
59(ab)

Technetium-99m HSA, In-111 platelets and, 
antithrombotic drug effects on platelet
deposition, carotid atheroclerosis, 701(ab)

Technetium-99m IDA, septo-optic dysplasia, 
neonatal jaundice, 966

Technetium-99m(III) carbonyls, development, 
myocardial perfusion imaging agents, 1870

Technetium-99m isonitrile

cardiac transport, hypoxia and, 620(ab)

myocardial imaging, 13

myocardial perfusion imaging, ischemic heart
disease, 675(ab)

Technetium-99m LDL, lipoprotein receptor
Thallium-201
correlation
Thallium-201
correlation cardiac multivessel high extravasal, SPED' scan perfusion perfusion-function myocardial MRI energy washout exercise 658(ab)
and, and, comparison, identification, infarction, method, 642(ab)
stress N-13 ammonia PET comparison, myocardial ischemia, subclavian vein obstruction, 254(e)
exercise SPECT, silent ischemia in, 589(ab)
exercise SPECT, silent ischemia in, 589(ab)
extravascular, local radiation dose from, 684(ab)
fast washout of, myocardial infarction, 945 Gd-67 uptake ratio, pulmonary neoplasms, 707(ab)
high grade astrocytoma, tumor/cardiac ratio method, 706(ab)
Hodgkin's disease, with hypercalcemia, 112 1-123 ITPA comparison, coronary artery disease, 669(ab)
intravenous dipyridamole and, elderly patients, 670(ab)
kinetics, hypoxia effects, myocardial cells, 1453 left ventricular mass measurement, heart rate and contractility effects, 408(ab)
lung-heart ratio, coronary artery disease, 1531 MRI combined with, myocardial ischemia and infarction, 703(ab)
multivessel PTCa outcome, accurate identification, 631(ab)
myocardial infarction, ischemia and, segment comparison, 260(ab)
myocardial rotational tomography, without myocardial infarction, 588(ab)
myocardial SPECT quantitation energy weighted acquisition, 577(ab)
wall thickness effects, 577(ab)
myocardial uptake, alterations in perfusion and oxidation, heart, 878
normal images, strongly positive exercise ECG and, prognosis, 643(ab)
perfusion-function imaging, CAD, 597(ab)
perfusion scintigraphy, EKG T wave normalization, 673(ab)
planar studies, CAD, new approach to interpretation, 588(ab)
post-exercise motion, perfusion defects and extent of ischemia, 598(ab)
post-perfusion scintigraphy, coronary angioplasty following thrombolysis, myocardial salvage, 674(ab)
quantitation, SPECT error maps for, 631(ab)
scan defects, prognosis in CAD, 643(ab)
SPECT alterations in distribution, chronic hypertension, 673(ab)
antianginal medical effects, 644(ab)
bullseye display, sex differences, 642
cardiac events and risk, elderly patients, 644(ab)
coronary stenosis, 666(ab)
dipyridamole with, coronary disease, 642(ab)
image artifacts that decrease specificity, 672(ab)
image interpretation, feature extraction, 618(ab)
isoproterenol infusion, assessment of myocardial perfusion after, 621(ab)
LAD disease with left bundle branch block, 589(ab)
left-ventricular aneurysm, 168
leg muscle perfusion, 717(ab)
motion during, 642(ab)
myocardial infarct size, 325
peripheral arterial disease, leg, 717(ab)
prediction of death and myocardial infarction, CAD, 644(ab)
quantitative criteria to read defects, 674(ab)
stress-induced myocardial perfusion defects, 642(ab)
stress N-13 ammonia PET comparison, myocardial ischemia, 567(ab)
subclavian vein obstruction, 254(e)
Te-99m MIBI and TBI comparison, biodistribution, heart, 654(ab)
Te-99m MIBI comparison coronary artery disease, 654(ab)
 improvement in scar, nonlinear regression transformation technique, 687(ab)
myocardial perfusion scintigraphy, coronary disease and, 654(ab)
quantitative myocardial imaging, 653(ab)
uptake, myocardial cells, 667(ab)
Te-99m RP-30 comparison coronary heart disease, 620(ab)
myocardial uptake, workload effects, 666(ab)
thrombolytic therapy, nuclear cardiology techniques, 632(ab)
tomograms, myocardial, 673(ab)
tumor vs. sarcoidosis differentiation, hilar and mediastinal adenopathy, 561(ab)
uptake blood flow relations and, heart, 399(le), 400(le)
exercise and dipyridamole effects, myocardial, 588(ab)
Thallium-201 DDC autorigraphic comparison, cerebral blood flow tracers, 481
vs. Te-99m HM-PAO, subcellular distribution, 593(ab)
Therapeutic nuclear medicine B-cell lymphoma, autologous bone marrow transplant and I-131 anti-Ida, 692(ab)
between patient variation in strontium, SR-89 dosimetry, 683(ab)
Br-80m labeled estrogen receptor binding ligands, synthesis and biodistribution, 572(ab)
generalized dosimetry schema, tumor uptake of monoclonal antibodies, 680(ab)
I-131 accumulation, pericardial effusion, 133(le)
I-131 lipiodol, hepatoma, 707(ab)
I-131 MBG diagnosis of carcinoid syndrome, 658(ab)
nuclear crest tumors, 308
pheochromocytoma and neuroblastoma treatment, 627(ab)
toxicity, blood radiation dosimetry, 618(ab)
in vivo generator, radioimmunotherapy, 721(ab)
I-131 therapy, parotid oncocytoma, 562(ab)
low vs. high dose I-131, thyroid remnant ablation, 686(ab)
skeletal metastases, 626(ab)
Sm-153-EDTMP osseous metastasis, 708(ab)
primary bone cancer, 709(ab)
thyroid cancer, hematologic long-term hazards, 581(ab)
Tungsten-188/Rhenium-188 generator, 656(ab), 657(ab)
Y-90, liver tumors, 708(ab)
Thiolates, chemistry and design implications, 593(ab)
Thoracic surgery, gallium uptake and, chest, 1831
Thorumbi, deep venous, detection with In-111 antibrin monoclonal antibodies, 1930(ab)
Thrombolysis coronary, myocardial perfusion and metabolism, PET, 1563
intracoronary, automated edge detection techniques, 135(le)
Thrombomodulin, deep vein, In-111 platelet scintigraphy, 649(ab)
Thrombosis deep vein, Tc-99m RBC venography role in, 649(ab)
experimental, In-111 and In-125 anti-platelet antibody behavior, 720(ab)
intracardiac, detection by In-111 platelets, blood-pool subtraction effects, 639(ab)
pregnancy, radionuclide venography, 1290
Thrombus left atrium, Ga-67 imaging, 691(ab)
prevention with Ga-67-DFO-DAS-fibrogen, following myocardial infarction, left ventricle, 609(ab)
Thymidin C-11 development as an imaging agent, 728(ab)
dosimetry estimates for PET studies, 683(ab)
Thymidine nucleotides, cellular sources, PET, 1435
Thymus, lymphoid and non lymphoid tumors, Ga-67 localization, pediatric patients, 293
Thyroglobulin, serum TSH and thyroidal disorders, atomic bomb survivors exposed in youth, 1115
Thyroid auto-transplanted, TI-201 imaging in, 1230(e)
cancer, differentiated, risk factors, 576(ab)
newly developed monoclonal antibodies against, 714(ab)
TI-201 correlation with I-131 and thyroglobulin assays, 686(ab)
diagnosed metastases, therapeutic dose of I-131, 1881
Thyroid carcinoma differentiated, TI-201 imaging, 685(ab)
imaging of metastases, 1782(le)
imaging with F-18 FDG, 910
congenital hypothyroidism, scintigraphy, 687(ab)
differentiated carcinoma, thyroglobulin levels and I-131 total body scan in, 685(ab)
disorders, atomic bomb survivors exposed in youth, 1115
functional volume, determination by SPECT, 575(ab)
longitudinal emission tomography, 1892
malignant cell line, labeled immunoglobulin aggregates to, 711(ab)
medullary carcinoma I-131 MBG uptake in, 265(ab), 576(ab), 1820
radiolabeled monoclonal antibody to
calcitonin in, 263(ab)
skeletal bone mineral density in, 685(ab)

Tc-99m DMSA in imaging of, 252(le), 253(le), 561(ab)

metastatic carcinoma, large dose radiiodide therapy for, preleukemia following, 1348
multimodality imaging of, 122

nodular disease
fine needle aspiration biopsy, 575(ab)
MR/RN correlation, 685(ab)
radiodiode dose reevaluation, newborn, 1208
remnant ablation

correlation of scan findings and quantitative uptake, 687(ab)

low vs. high dose I-131(ab)
screening, I-131, after Chernobyl accident, 535
thyroxine replacement therapy, elevated T4 levels in, 575(ab)

Thyroid disease, free thyroxine index, thyroxine binding globulin assay in, 1341

Thyroiditis, subacute, presenting as painless cold nodule, 1488

Thyroid-stimulating hormone (TSH) radiiodimunomass kit, simultaneous free T4 and, 719(ab)

thyroglobulin and thyroid disorders, atomic bomb survivors exposed in youth, 1115

Thyroxide elevated levels, patients on thyroxine replacement therapy, 575(ab)
free estimation, analog assays employing chemical blockers, 568(ab)
simultaneous free, TSH radioimmunomass assay kit and, 719(ab)

thyroxine, free index, calculation in normal, thyroid disease, and sick euthyroid patients, 1341

Thyroxine-binding globulins, free thyroxine index, calculation in normal, thyroid disease, and sick euthyroid patients, 1341

Transplantation, heart-lung, tracheobronchial ciliary function in, 616(ab)

Tricarboxylic acid, myocardial cycle tracer, C-11 labeled acetate, 611(ab)

Tumor necrosis factor, radiolabeled metabolic probes in, liver, 640(ab)

Tumors
activity, compensation for attenuation, SPECT, 577(ab)

antigen density, new in vitro method, 719(ab)

brain characterization by parametric imaging of blood volume, FDG and metabolism, 645(ab)
incorporation of amino acids in, 595(ab)

TI-201 scintigraphy, 658(ab)
carcinoid, imaging with I-123 MIBG, 1907

colorectal, SPECT perfusion imaging, 408(ab)
drug metabolism in, non-invasive monitoring, 595(ab)

Gd-153 chelates, distribution and relativity, 705(ab)
gliomas, PET evaluation of, 1123

high grade astrocytoma, tumor/cardiac ratio method, 706(ab)

hypoxia, F-18 fluoromisonidazole, 594(ab)
immunodetection, implications for, 711(ab)
intraperitoneal, monoclonal antibody delivery, 715(ab)
localization, clinical parameters related to, 25 lymphoid and nonlymphoid, thymic localization of Ga-67, pediatric patients, 293
malignant brain, assessment of chemotherapy, 1807

cisplatin PET, 1844
malignant gliomas, F-18 FDG, 645(ab)

methanol, comparison of size, In-111 antibody, 711(ab)

monoclonal antibody uptake in, model related to surface area, 713(ab)
neural crest, I-131 MIBG diagnosis and therapy, 308, 178(ab)
neuroendocrine, I-131 MIBG scintigraphy in, 979

nude mouse-human model, In-111 monoclonal antibody intratumoral injection, 712(ab)

oxygination, monoclonal antibody uptake and, 709(ab)

para-axial neurofibromatosis, SPECT with Tc-99m DTPA, 1688

parotid oncocyoma, radioactive I-131 therapy for, 626(ab)

pheochromocytoma and neuroblastoma, I-131 MIBG scintigraphy, 315

pituitary, dopamine D2 receptors in, 626(ab)
primary pericardial mesothelioma, Ga-67 citrate detection of, 1201

pulmonary neoplasms, Ga-67 to TI-201 uptake ratio, 707(ab)

radiolabeled monoclonal antibody metabolism, methods for study, 390

regional recurrence, sternal lesions in breast cancer, 606(ab)
response to chemotherapy, Tc-99m HM-PAO and Rb-86 chloride as markets of, 595(ab)
skeletal, therapeutic nuclear medicine, 626(ab)

squamous cell, lung, immunoscintigraphy, 637(ab)

targeting, highly immunoreactive monoclonal antibodies, 651(ab)

transplantable, metabolic fate of L-glutamate, 594(ab)

uptake, monoclonal antibodies, 715(ab)

Y-90 monoclonal antibodies, purification method and coinjection, 721(ab)

Tumor-seeking agents
abdominal colorectal cancer, SPECT, 604

against synthetic carbohydrate antigens, cancer immunoscintigraphy, 712(ab)

antibody DTPA conjugates with different linkages, comparison, 572(ab)

antibody tumor targeting, chemical modification with ester bond, 572(ab)

avidin and biotin, imaging applications, 560(ab)

B-cell lymphoma, 692(ab)

blood clearance of, ester bonds, 602(ab)

brain tumor imaging, 47

breast tumor imaging, radiolabeled bacterial immunomodulator, 658(ab)

chimeric antibodies, immunoscintigraphy with, 561(ab)

chimeric monoclonal antibody, characterization by I-125, 560(ab)

chronic lymphocytic leukemia with, radiocarcinogenocysstigraphy, 602(ab)

clonic cancer, whole-body autoradiography, 683(ab)

comparison of tumor size, melanomas, 711(ab)

continuous regional chemotherapy and, liver metastases, 706(ab)

coupling agents, tumor targeting and, 712(ab)

C-11 SarCNu, no carrier added, 625(ab)
detection of human melanoma, athmic mice, 708(ab)

F-18 FDG, imaging of thyroid carcinoma, 910

Ga-67 vs. In-111 DTPA, detection of metastatic melanoma, 573(ab)

gynecologic carcinoma, recurrences, 1807

hepatoma, hepatobiliographic imaging, 628(ab)

imaging of hypoxia, 68

immunocarcinography, clinical assessment, 637(ab)

In-111 chelation to monoclonal antibodies, 861

localization, melanoma, 651(ab)

In-111 and I-131 comparison, cutaneous T-cell lymphoma, 281

In-111 porphyrins, synthetic, 724(ab)
in vivo generator, radioimmunotherapy, 721(ab)

labeling of proteins, 721(ab)

long term fate, BALB-C mice, 692(ab)

medullary carcinoma, thyroid, 561(ab)

monoclonal antibody localization human colon carcinoma, 709

targeting radiopharmaceuticals, 561(ab)

monoclonal antibody uptake, tumor, model related to surface area, 713(ab)

monoclonal anti-colon/ovarian antibody, potential imaging agent, 710(ab)

MRI, melanomas in nude mice, 704(ab)

newly developed monoclonal antibodies, thyroid cancer, 714(ab)

non-specific Fc receptor binding, tumor detection, 572(ab)

optimal tumor localization, clinical parameters related to, 25

ossaceous metastasis, 708(ab)

pharmacokinetics, cancer patients, 714(ab)

radioimmunodetection, colon tumor model, 711(ab)

renal cell carcinoma, phase I-II trials, 603(ab)

Re-186, labeling of antibodies, 656(ab)

Re-188, generator system for therapeutic applications, 657(ab)

sensitive IRMA, detection of CA125 antigen, 568(ab)

subcutaneous injection of, lymphoma after, 42

Tc-99m antibody, known and occult metastatic melanoma, 573(ab)

Tc-99m DMSA, medullary thyroid carcinoma, 252(le), 253(le)

TI-201, differentiated thyroid carcinoma, 685(ab)

tumor xenografts, CE-DTS, 720(ab), 730(ab)

V-48 vanadyl(VI)-phosophorbide, cancer diagnosis, 723(ab), 727(ab)

Venography

duplex, correlation with nuclear scans, renal allograft rejections, 647(ab)

Tonsnen formula vs., kidney depth determination, 647(ab)

Urology tract
activity, 20 min fractional, 735(ab)

obstruction, volume expansion diuretic renal scan, 824

Urodilatometry, electronic, bladder emptying rate compared to urinary flow rate, 733(ab)

Venography
radioisotope
pregnancy, 1290

upper extremity and superior vena cava, 1794(ab)

Tc-99m RBC, role in suspected deep vein
Venous leakage

- thrombophlebitis, 649(ab)
- Venous leakage, detection, Xe-133 corporeal washout, 650(ab)
- Venous pump, staged maximal exercise and, contribution to cardiopulmonary blood volume, 650(ab)
- Ventilation-perfusion scan digital subtraction angiography comparison, pulmonary emboli, 584(ab)
radiation-induced lung damage, early detection with SPECT, 659(ab)
- Ventilation studies asymptomatic pulmonary embolism, following knee replacement, 584(ab)
extrapulmonary radioactivity, lung permeability measurements, 903
N-13, PET and, 587(ab)
radioaerosols, congenital lobar emphysema, 1213
regional, short-lived radiotracer, steady-state model, 1144
respiratory clearance, aerosolized radiopharmaceuticals, 894
Tc-99m PYP and DTPA aerosols, comparison for SPECT, 585(ab)
- Ventricular aneurysm, SPECT Thallium-201, 168
- Ventricular dysfunction, minimal or no symptoms, prognosis, 644(ab)
- Ventricular filling, analysis, CAD detection, 837
- Ventricular function left diastolic, age-related changes in CAD, 670(ab)
left dysfunction, chest pain and, CAD patients, 671(ab)
measurement, gated pressure-volume loop determinations, 676(ab)
myocardial perfusion and, Tc-99m RP-30, 662(ab)
regional dysenergy, radionuclide angiography, 1725
right, pre- and post-operative, valvular heart disease, 671(ab)
suction measurements, pressure-volume relations, 557(ab)
- Ventricular mass, measurement with TI-201, heart rate and contractility effects, 408(ab)
- Ventricular scans, gated xenon, 261(ab)
- Ventricular volume calculation, radionuclide, 578(ab)
determination by standard voxel counting, 579(ab)
enoximene effects, 669(ab)
left, attenuation-corrected radionuclide, 552(ab)
measurement, correction factor, 401(ab)
radionuclide measurement, attenuation coefficient, 1363(ab)
- Ventricular wall computer simulation of motion, finite element method, 557(ab)
damage, 266(ab)
- Ventriculoscopy age effects, maximal upright exercise, 578(ab)
dobutamine infusion, pediatric patients, 621(ab)
left ventricular functional recovery, after exercise, CAD, 579(ab)
myocardial ischemia, mental stress and, 597(ab)
radionuclide beyond the ejection fraction, 266(ab)
cardiac probe system, 670(ab)
coronary artery disease, 666(ab)
following thrombolytic therapy, 632(ab)
left and right ventricular function, spontaneous respiration effects, 173
mortality risk indicator, after myocardial infarction, 670(ab)
volume measurements attenuation coefficients for, 102
ventricular function, valvar regurgitation and, aortic or mitral valve lesions, 621(ab)
- Vertebral metastases, thoracic and lumbar spine, SPECT, 665(ab)
- Vesicoureteral reflux, siblings of children with, silent renal damage, 621(ab)
- Vitamin B12, analog, synthesis, 636(ab)
- Volume expansion diuretic renal scan, urinary expansion, 646(ab)

Voxel counting, determination of left ventricular volume, 579(ab)

Wada test
Tc-99m HM-PAO brain SPECT
blood flow, 592(ab)
epileptic patients, 1763

Xerox-133
balloon catheter and, measurement of liver blood flow, 628(ab)
brain SPECT, cryptogenic West syndrome, 592(ab)
coronary flow and, 609(ab)
corporeal washout, detecting venous leakage, 650(ab)
inhalation SPECT, demented patients, 599(ab)
lower extremity imaging, detection of venous thrombosis, 1792(ab)
mammary grafts, internal, 632(ab)
uptake, hepatic steatosis in kwashiorkor, 622(ab)
ventilation studies, lung, 616(ab)

Ytrrium-90
activable glass, radiotherapy of liver tumors, 708(ab)
- antibodies biodistribution in patients, 712(ab)
radioautolysis effects, 711(ab)
brake radiation dose due to, anthropomorphic phantom, 684(ab)
generator-produced, radioimmunotherapy, 1465
inhahepatic infusion, radiotherapy by, 707(ab)
- monoclonal antibodies selective cytotoxicity, malignant T-cell line, 710(ab)
unlabeled, purification method and coinjection of, 721(ab)
REFERENCES

References must be typed double spaced on a separate sheet and numbered consecutively as they are cited in the text. References included in a table or illustration are also numbered sequentially with those in the text. When more than three authors appear, the additional authors are listed as "et al." The Journal uses the Index Medicus style for references. Journal names are abbreviated according to the List of Journals Indexed in Index Medicus. Sample references are:


Numbered references to personal communications, unpublished data, manuscripts in preparation, or manuscripts submitted for publication are not acceptable.

TABLES

Tables should be self-explanatory and supplement, not duplicate, the text. Each table must be cited in numerical order in the text and typed on a separate sheet of paper after the references. Number the tables consecutively with an Arabic number following the word TABLE. The titles should be descriptive, brief, and centered in upper and lower case letters. Include explanatory material in the footnotes or the text. Place horizontal lines below the title, below column headings, and at the end of the table. Do not use vertical rules.

ILLUSTRATIONS

Illustrations should be limited to those which clarify and augment the text. Since imaging is one of the major aspects of nuclear medicine, the selection of high-quality halftone illustrations is of paramount importance. High-contrast glossy prints should be submitted instead of film. Original line drawings and graphs are preferred for optimal reproduction and should be rendered professionally on white drawing paper in black India ink. Template or typeset lettering should be used. No hand drawings, typewritten art, or computer-generated art will be accepted. Figures of inferior quality will be returned to the author for correction and replacement. Details to be emphasized or crop marks should be indicated on a tissue overlay. Each illustration must be numbered and cited in order in the text. The following information should be typed on a gummed label and affixed to the back of each illustration: figure number, senior author, title of manuscript, and row indicating "top." Authors are responsible for the costs of color reproduction.

LEGENDS FOR ILLUSTRATIONS

Submit a separate legend page with descriptive paragraphs for each figure, typed double spaced in numerical order with an Arabic number following the word FIGURE. If illustrations have been published previously, authors are responsible for obtaining permission to reproduce them from both the original author and publisher. The source must be cited in the references and the following credit line must appear in the legend: (Reprinted by permission of Ref. X.) All permission releases must be submitted to the Editor at the time of acceptance.

UNITS AND ABBREVIATIONS

Nomenclature, units, and abbreviations should conform to IUPAC recommendations and Systeme Internationale (SI). Chemical formulae follow the recommendations of the American Chemical Society.
### Index to Advertisers

<table>
<thead>
<tr>
<th>Advertiser</th>
<th>Telephone Number</th>
<th>Page Number</th>
<th>Reader Service Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atomic Products</td>
<td>(516)924-9000</td>
<td>14A</td>
<td></td>
</tr>
<tr>
<td>Biosources</td>
<td>(800)248-2006</td>
<td>30A</td>
<td></td>
</tr>
<tr>
<td>Data Spectrum Corporation</td>
<td>(919)942-6192</td>
<td>10A</td>
<td></td>
</tr>
<tr>
<td>Diagnostix Plus, Inc.</td>
<td>(516)742-1939</td>
<td>11A</td>
<td></td>
</tr>
<tr>
<td>Diversified Diagnostic Products, Inc.</td>
<td>(713)955-5323</td>
<td>8A</td>
<td></td>
</tr>
<tr>
<td>Elscint, Inc.</td>
<td>(617)739-6000</td>
<td>7A</td>
<td></td>
</tr>
<tr>
<td>General Electric Medical Systems</td>
<td>(800)624-5692</td>
<td>9A</td>
<td></td>
</tr>
<tr>
<td>GNI Incorporated</td>
<td>(713)332-3581</td>
<td>IBC</td>
<td></td>
</tr>
<tr>
<td>JRT Associates</td>
<td>(914)693-3939</td>
<td>11A</td>
<td></td>
</tr>
<tr>
<td>Medi-Physics, Inc.</td>
<td>(800)MEDI-123</td>
<td>IFC, 1A, OBC</td>
<td></td>
</tr>
<tr>
<td>Nuclear Associates</td>
<td>(516)741-6360</td>
<td>2A</td>
<td></td>
</tr>
<tr>
<td>Radiology Research and Education Foundation</td>
<td>(415)476-5808</td>
<td>30A</td>
<td></td>
</tr>
<tr>
<td>Trionix Research Laboratories</td>
<td>(216)425-9055</td>
<td>12A, 13A</td>
<td></td>
</tr>
<tr>
<td>Information for Classified Advertisers 1988</td>
<td></td>
<td>20A</td>
<td></td>
</tr>
<tr>
<td>SNM Councils</td>
<td></td>
<td>27A</td>
<td></td>
</tr>
<tr>
<td>SNM Meetings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Meeting Call for Scientific Exhibits</td>
<td></td>
<td>23A</td>
<td></td>
</tr>
<tr>
<td>Winter Meeting</td>
<td></td>
<td>30A</td>
<td></td>
</tr>
<tr>
<td>SNM Membership</td>
<td></td>
<td>24A, 25A, 26A</td>
<td></td>
</tr>
<tr>
<td>SNM Publications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chromatography of Tc-99m Radiopharmaceuticals</td>
<td></td>
<td>29A</td>
<td></td>
</tr>
<tr>
<td>Patient Pamphlets</td>
<td></td>
<td>19A</td>
<td></td>
</tr>
<tr>
<td>SPECT, A Primer</td>
<td></td>
<td>28A</td>
<td></td>
</tr>
</tbody>
</table>